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FOREWORD
Camptothecin (CPT) is a secondary metabolite formed
by a tree, Camptotheca acuminata Decaisne, which is a
native of China. During the period 1950-1960, I was the
director of a group of chemists at the Eastern Regional
Research Laboratory, USDA, searching the Plant Kingdom
for plants which might contain suitable precursors for the
synthesis of cortisone, a recently discovered anti-
inflammatory agent then in short supply. USDA botanists
collected more than 7,000 plant samples. A number of
these had never received chemical examination, hence we
saved extracts of these plants. One of these extracts was
prepared from the fruit of C. acuminata. In 1957, Dr.
Jonathan Hartwell, NCI, visited my laboratory and
requested available plant extracts for antitumor testing in
mice. I readily complied, and by 1958 learned of the
extraordinary activity of C. acuminata extracts. In 1960, I
joined the Research Triangle Institute and organized a
natural products group, which was joined in 1962 by my
long time collaborator, Dr. M.e. Wani. This led to the
isolation and structure elucidation of camptothecin from
bark and wood of C. acuminata trees in 1966. A few years
later in 1971, our same group isolated taxol.
Drs. Shiyou Li and Kent T. Adair have prepared a
monograph which reviews in a thorough manner the
subsequent history of CPT and analogs from discovery to
xpromiSIng clinical drugs. In addition, the monogr<lph
provides a wealth of nove I data concerning botanicaL
ecological, agronomical, and cultural information, much
of it presented for the first time in this interesting
monograph.
Monroe E. Wall, Ph.D.
Chief Scientist
Chemistry and Life Science~
Research Triangle Institute
Research Triangle Park, NC
September 1994
PREFACE
This book appears at a time when interest in
camptothecin and its derivatives is beginning to grow
exponentially. Interestingly, the product(s) of Camptotheca
tree have been known for quite a few years since the
finding that Camptotheca extracts possess anticancer
activity and the isolation and characterization of the active
component, camptothecin, respectively, in 1958 and 1966.
Unfortunately, there was a false start due to the use of the
sodium salt for clinical trials instead of the natural product
because of the good water solubility of the salt. When the
salt was found to be inactive and toxic, as it is,
camptothecin was assumed to be also inactive and
discarded, a classical case of throwing the baby away with
the water. A period of eclipse followed but not of inactivity.
It was found that camptothecin is the main inhibitor of
DNA topoisomerase I, explaining its mechanism of action
as cell growth inhibitor and a big clue to its anticancer
activity. Water soluble derivatives were synthesized, some
of which maintained part of the anticancer activity of the
mother compound. Finally, a series of water insoluble
derivatives was synthesized by Wall and Wani which, in
1989, were found to have anticancer activity superior to
camptothecin. The difference in activity between
camptothecin and its sodium salt was established.
Camptothecin itself was re-evaluated and successfully run
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through Phase I Clinical Trials at the Stehlin Foundation,
demonstrating tolerable toxicity almost exclusively of
intestinal origin. Phase II Clinical Trials are now due to
begin treating breast cancer by oral administration at the
Stehlin Foundation and at Dana Farber Cancer Institute in
Boston. Another non-water-soluble derivative, 9-amino-
camptothecin, has undergone Phase I Clinical Trials at
Dana Farber and at the Naval Hospital in Bethesda
administered intravenously in a special solvent. Other
derivatives are under study and in various phases of
development for utilization as anticancer, antiviral, and
antiparastic drugs. It appears that we are now poised for
the big leap forward of this group of compounds into
practical utilization of the potent biological activity of
camptothecin and its derivatives. This book is arriving at
the right moment, bringing a large amount of very welcome
basic information on the subject.
Beppino C. Giovanella, Ph.D.
Laboratory Director
The Stehlin Founda hon for
Cancer Research
Houston, Texas
October 1994
AUTHORS' PREFACE
Many important scientific discoveries are made
retrospectively. One well-known example is the
rediscovery of Mendel's findings in genetics. However,
camptothecins, promising anti-tumor drugs extracted from
Xi Shu (Chinese happytree, Camptotheca acuminata
Decaisne), are a recent example. Dr. M. E. Wall at
Research Triangle Institute found the anti-tumor activity
potential of camptothecin about thirty years ago.
However, studies were almost abandoned in the United
States for nearly two decades after a finding of high
toxicity. Recently, the drugs were "rediscovered" in the
United States as promising drugs. Consequently, Xi Shu
extracts are now in a position to playa major role in the
fight against cancers.
Taxol, a potent anti-tumor drug that was first isolated
from the bark of the Pacific yew (Taxus brevifolia) by
Dr. Wall and associates in 1971 recently caused a stir
throughout the scientific community. It brought new hope
to millions of cancer patients. The clinical trials show that
taxol is particularly outstanding for ovarian cancer.
Camptothecins, are also very valuable drugs with different
uses. Chinese and Japanese long-term clinical trials since
1970 show that camptothecins have a broad spectrum of
medical uses. The recent discovery of its unique
mechanism of action has shown the clinical value of the
drug. Dr. B. C. Giovanella, world-renowned scientist from
the Stehlin Foundation for Cancer Research in Houston,
clearlv stated that camotothecin is the most promi8in~
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anti-cancer drug that has ever been found. In addition,
recent experiments show camptothecins have activity
against many DNA viruses and even some RNA viruses,
including retroviruses that cause some severe diseases in
humans and animals. Xi Shu, as the main botanical source
of camptothecins, grows very fast, up to about 1.6 meters
a year in favorable conditions, and all parts can be used for
dru.g extractions. All these features give Xi Shu status as
an anti-tumor plant in drug development. Thus, Xi. Shu
provides renewed hope for cancer treatment.
It is expected that at least 100 million young Xi Shu
will be needed annually for the drugs camptothecins in the
United States in very near future. However, the seed
source is scarce and the gene pool is very small in the
United States. Thus, the drug supply will be limited by the
Xi Shu supply. This monograph is an update summary of
botanical, ecological, chemical, and medical research on Xi
Shu. And the bibliography includes about 1,300
publications in English, Chinese, Japanese, and other
languages. Hopefully, it provides a stimulus and guide to
further studies, especially in resource development, of drug
derivatives from this very interesting tree.
Shiyou Li, D.F.
Kent T. Adair, Ph.D.
Nacogdoches, Texas
August, 1994
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1. INTRODUCTION
Cancers and Taxa]
Today, about 75% of the world's population still relies on
plants or plant extracts as traditional medicine for primary
health care. There are 119 pure chemical substances
extracted from higher plants that are clinically used
throughout the world (Farnsworth 1988). These plant-derived
drugs are obtained from less than 90 species, or only 0.036%
of the total 250,000 described plant species. Extensive studies
of plants for possible medical applications are very limited.
Regardless, the finding of each new drug brings new hope for
humans and may even cause a revolution in human life itself.
Taxol, for example, an alkaloid that was first extracted from
the bark of the native Pacific yew (Taxus brevifolia Nutt.) by
Dr. Monroe E. Wall in 1971 has recently caused a stir
throughout the scientific community as a very promising drug
in the treatment of certain cancers. Several thousand
terminal cancer patients have taken taxol since trials began in
1983 (Joyce 1993). These clinical trials have confirmed that
taxol can shrink tumors by at least one half in 20 to 30% of
patients with refractory ovarian cancer. The Food and Drug
Administration (FDA) approved taxol for general use in
advanced ovarian cancer in 1992. The result is a multi-billion-
dollar industry with an international network to produce
taxa!. Consequently, for a time, the Pacific yew became one of
the most valuable plant species in the world. However, three
major obstacles limited early development of the drug: source
scarcity, toxicity, and poor water solubility.
The short supply of the Pacific yew was a critical problem.
Currently, 20,000 women are diagnosed with ovarian cancer
and 12,000 die each year in the United States (Murray 1991).
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The National Cancer Institute (NCI) of the National Institutes
of Health (NIH) contracted with Bristol-Myers Squibb to
obtain 337,500 kg (750,000 pounds) of yew bark a year to meet
this requirement (Johnson 1992). This requires up to 144,000
new mature trees each year because stripping the bark (at
that time the sole source of the drug) kills the tree. In 1993,
about 1,170,000 people in the United States were diagnosed as
having cancer and 526,000 died of this disease (Boring et a1.
1993). Each year one in ten women is confronted with breast
cancer and must make decisions regarding treatment (Scanlon
1991). If taxol is approved for treatment of some of these
cancers (e.g., breast cancer), the annual demand for yew could
jump to many millions of trees. However, it is estimated that
the total number of yew trees with trunks of 25.4 em (10
inches) or more in diameter is only 1.2-4.0 million (Murray
1991, Joyce 1993). This is not enough to meet a single year's
total demand in the United States alone! Moreover, the yew is
one of the world's slowest-growing species, it takes 100 years
or more to mature. To meet the demand for taxol, an
international effort, led by Bristol·Myers Squibb, taxol's only
manufacturer, has been undertaken to look for new ways to
provide taxol, especially semisynthetic procedures using the
needles and top portions of Taxus baccata, a shrub, and
production of totally synthetic taxa!. In early 1994, two
groups of scientists (K. C. Nicolaou of the Scripps Research
Institute and R. Holton of Florida State University) announced
a total synthesis of taxa!. Unfortunately, according to
Matthew Suffness, a chemist in the NCI, neither of these two
groups' methods are likely to be commercially viable at this
early stage; even after the synthesis technique has been
refined, it may be less expensive to make commercial taxo}
out of trees (Flam 1994). Also, the synthesis of taxol cannot,
in any way now known, increase the drug supply in the near
future. Moreover, toxicity and poor solubility of taxol make it
hard to administer, and tumor cells tend to develop resistance
to the drug thus making Xi Shu an attractive source of
camptothecin for treatment of some forms of cancer.
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Camptothecins and Hope
Camptothecin (CPT, also known as camptothecine) and its
analogs are promising anti-tumor drugs with many different
uses (Table 1). The drugs are extracted from Xi Shu
(Camptotheca acuminata Decaisne), a Chinese deciduous tree
of the family Nyssaceae, and have unique mechanisms of
action. Unlike taxol and its analogs that can be extracted
principally from bark of mature yew trees, camptothecins can
be collected from all parts and all ages of Xi Shu. Also, recent
experiments showed that camptothecins have activity against
viruses including retroviruses, the causative agents of
acquired immune deficiency syndrome (AIDS) and many other
severe diseases in humans and animals (Priel et 1991, 1993, Li
et a1. 1994a, b; Table 2).
The anti-tumor activity of Xi Shu was discovered in 1957
(Perdue et aI. 1970) and its anti-viral activity was reported in
1971 (Horwitz and Horwitz 1971). These activities have been
emphasized recently. The isolation of CPT, a potential drug
extracted from Xi Shu, was accomplished in 1965, several
years earlier than that of taxa!' The first report of clinical
trials of CPT appeared in 1970 (Gottlieb et a1. 1970); thirteen
years earlier than those of taxo1. Unfortunately, further
investigation of CPT ceased several years later in the United
States because of the severe, unacceptable bladder toxicity of
the sodium salt, which was thought a necessity for effective
use of CPT. However, the use of CPT in clinical trials has
continued in China since 1970.
In China CPT is directly used in treatments, not with the
toxic sodium salt. Also, 10-hydroxycamptothecin, a less toxic
and more effective analog of CPT, has been successfully used
to treat liver, neck, and head cancers in China. The discovery
in 1985 that camptothecins uniquely inhibited the activity of
the DNA topoisomerase I (topo I) along with the factors
mentioned above resulted in a rapid resurgence of
international research and commercial interest in these drugs.
Xi Shu promises to be one of the most important anti·tumor
and probably also anti-viral trees worldwide.
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TABLE 1. General profiles of camptothecins and taxols.
Property Camptothecins Taxols
Main Source
Anti-viral
Activity
Anti-tumor
Activity
Xi Shu
(Camptotheca acuminata)
Discovered in 1957 and
documented in 1966 by M.E.
Wall and co-workers (perdue
ct aL 1970)
Reported in 1971 by Horwitz
and Horwitz (1971) and
emphasized in the early
1990s by others
Drug Isolation In 1965
Pacific yew
(Ta.xus brevifolin)
Discovered in 1963 and
documented in 1966 by M.E.
Wall and co-workers
(Hawkins 1992)
No
In 1971
Chemical
Classification
Water
Solubility
Toxicity
Physiological
Action
Parts for Drug
Extraction
Plant Supply
Tree Growth
Quinoline
CPT is insoluble, and some
analogs are water-soluble
Sodium salt: toxic;
suspension: less toxic
Inhibit DNA synthesis
through stabilizing the
cleavable complex of DNA
and the enzyme
topoisomerase I
All parts (stem, stem bark,
leaf, root, root hark, and
fruit)
Short, not native and rare
cultivation in the United
States
Fast, 20 years to maturity,
up to 30 m tall
Complex diterpcne
Insoluble, and some analogs
are water-soluble
Toxic
Binds to mitotic spindles so
that cells cannot replicate
Stem bark
Short, native but rare in the
United States
Slow, 100 years to maturity,
up to 15 m tall
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TABLE 2. Citations on the uses of camptothecins cross-referenced
to taxols.
Use Camptothecins Taxols
Clinical Trials First reported in 1970, First reported in 1983,
and Responses in mostly from the United mostly from the
Cancers: States, China, and Japan United States
Breast 1a 37,38
Central Nervous 81a
Colon & &ctum la, 3,5, 7c, 8c, 9, Ub,29c,
30a, 36c, 64, 72ac, 73a,
76a, 77a
Esophageal lOa,70ac
Head 6, lIb, 36c 39
Kidney la, 35a 40
Leukemia 3, 12c, 13, 14a, 68a
Liver lIb
Lymphoma lIb, 12c, 28c
Melanoma l,15,36c 41,42
Neck 6, lOa, 36c 39
N on-small-cell la, 3, 4, 16a, 18a, 19c, 21c, 43-45
Lung 22a,23c, 24c, 25c, 26c, 27c,
48c, 71bc, 75c, 78c, 79c,82
Ovarian 1a,2c, 16a, 17c, 36c, 69ac 46-48,65
Prostate 80 49,66
Psoriasis 32-34
Small-cell Lung 18a,20c,25c,35a, 78c,
79c,82
Stomach 4,6,15,35a
Testis 36c
Trophoblastic lIb
Urinary Bladder 6,30a 67
Uterine Cervix 2c, 7c, 17c, 36c, 74c
Anti-viral Activity 51-56
Insect Chemo-
sterilant 57,58
Plant Growth
Regulator 59-63
42-Lcgha el al. 1990;
43-Chang et al. 1992, 1993;
44-Murphy ct al. 1992, 1993;
45-Eiscnhauer 1993;
46---McGuire et a1. 1989;
47-Thigren et a1. 1990;
48-Einzig et al. 1990, 1992;
49-Roth et a1. 1992;
50---Shinkai el al. 1994;
51-Prielet al. 1991;
52-Priel et a1. 1991;
53---eheng et aI. 1992;
54-Kerr et a1. 1993;
55-Priel et a!. 1993;
56-Li ct al. 1994a, h;
57-DeMilo and Borkovec 1974;
58-Hunan Institute 1978;
59-Bula and Worley 1976;
60---Worley ct al. 1979;
61-Buta and Spauding 1986;
62-Tao and Buta 1986;
63-Buta and Kalinski 1988;
64-Giovanella et al. 1989;
65-Caldas and McGuire 1993;
66---Yeap and Wilding 1993;
67-Rangc1 ct al. 1994;
68-KantaIjian ct al. 1993;
69-Johnson 1992a;
70--Johnson I992b;
71--Johnson 1992c;
72--Johnson 1993;
73-Burris et al. 1992;
74--Takeuchi 1992;
75-Negoro 1991;
76---Haas et al. 1992;
77--Haas et al. 1994;
78-Niitani 1991;
79-Fukuoka 199 1;
gO-Stehlin Foundation 1993;
81-Friedman el at 1994;
82-Burris 1993.
6 XI SHU
NOTES TO TABLE 2.
Subscripts: a-topotecan (TPT); b-lO-hydroxycamptothecin (HCPT); c-
irinotecan (CPT-ll); others---camptothccin (CPT); ----no data available.
References (see Literature Cited):
I-Burris et al. 1992;
2-Takeuchi et al. 1991a, h;
3-Gottlicb cl al. 1970;
4-Muggia ct a1. 1972;
5-Moertel et a1. 1972;
6-Xu et al. 1979;
7-Rowinsky et al. 1992;
8-Gandia et al. 1992;
9-Bertrand et al. 1992;
10000SiroU et al. 1991;
II-Shanghai Institute 1975;
12-0hno et aI. 1990;
13-Furuta and Yokokura 1991;
14-Beran et al. 1992;
15-Gottlieh and Luce 1972;
16-Rowinsky ct al. 1992;
17-Takeuchi et al. 1992;
18-Verweij et al. 1992;
19-Masuda cl al. 1992;
20---Masuda et al. 1992;
21-Musuda et al. 1993;
22-Lynch et al. 1994;
23-Shinkai et a1. 1994;
24-Noriyuki et a1. 1994;
25-Negoro et al. 1991;
26-Fukuoka et al. 1992;
27-Kanzawa et al. 1992;
28-Tsuda ct al. 1992;
29-Shimada et a1. 1993;
30-Hass et al. 1992;
31-Gu et al. 1987;
32---ehiao and Li 1974;
33-Lin 1987;
34-Lin et al. 1988a, b;
35-Saltz et al. 1993;
36-Abigerges et al. 1994;
37-Holmes et al. 1991;
38-Seidman et al. 1992;
39-Forastiere 1993;
40-Einzig et al. 1988a;
41-Einzig et al. 1988b;
CAMPTOTHECINS,
PROMISING DRUGS
'ILife is) limiteb. but knobJlebge is) HmitleS)!i.
-Zuang Zi (c. 4th-3rd century B.C.)

2. HISTORICAL REVIEW
Discovery of Camptothecins
It is widely recognized that Xi Shu had little human use in
its native region of China before the 19608 (Perdue et a1.
1970). The discovery of its anti-tumor activity has now made it
the "Cinderella of the forest."
Recognition of the anti-tumor activity of CPT was
established in the United States at about the same time as
taxol. In 1950, the United States Department of Agriculture
(USDA) began a search of the world's plant resources for
species that produce chemical substances which could be
converted to cortisone. The chemical branch of the USDA
involved in this program was located at the Eastern Regional
Research Laboratory, Philadelphia, Pennsylvania, and was
under the direction of Dr. M. E. Wall. Xi Shu was one of the
plant materials supplied by the Chico Plant Introduction
Station in California for the cortisone program. However, an
extract of leaves was negative in a test for cortisone
precursors. The unused extract was placed on the laboratory
shelf where it remained for almost six years. In 1957,
Johnathan Hartwell of the Cancer Chemotherapy National
Service Center (CCNSC), National Cancer Institute started a
plant anti-tumor screening program. Of 1,000 ethanolic plant
extracts for testing for antitumor activity sent by Wall, the
crude extract of the leaves of Xi Shu were the only ones to
have high activity in two tumor systems. But only two trees
were known in Chico as the remaining living specimens in the
United States. This supply was inadequate to complete any
required series of tests (Perdue et al. 1970).
In 1960, Dr. Wall joined the Research Triangle Institute
in Durham, North Carolina. He and associates reviewed the
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anti-tumor screening data on the old extracts and requested
new supplies of Xi Shu. The Chico Station provided new
samples of leaves, twigs, and fruits in September 1961. Soon,
it was found that leaves were inactive but fruits and twigs
were active against lymphoid leukemia L1210 without toxicity
in vitro (Perdue et a1. 1970). By late 1963, Wall and associates
started intensive chemical research on isolation and
identification of the active compound from Xi Shu. In order to
provide adequate raw material for this program, a systematic
search for individual specimens of Xi Shu was undertaken
along the western coast of the United States. Finally,
thirteen trees were found in central and southern California
and most of these trees were removed for chemical tests. In
March 1965, from the stem wood of Xi Shu, Wall and his
colleagues successfully isolated a minute quantity of a pure
crystalline substance, CPT, which is responsible for Xi Shu's
anti·tumor activity (Wall et a1. 1966). The latter techniques
established that camptothecin (C2oH1604N2) is a pyrrolo (3,4,-
b )quinoline alkaloid, that is, 4(8 )-4-ethy1-4-hydroxy-IH-
pyrano-(3' ,4' :6,7)indolizino(1 ,2,-b)quinoline-3,14(4H,12H)-
dione (Figure I), The announcement of CPT's structure in
1966 caused considerable excitement in the scientific
community. The novel structure and significant anti-tumor
activity of CPT greatly stimulated scientists' research.
By 1969 isolation of the alkaloid was also completed in
China. Since then, a number of hydroxyl and methoxyl
derivatives have been reported by scientists in the United
States, China, and Japan. Wani and Wall (1969) first isolated
two minor compounds, 10-hydroxycamptothecin (HCPT)
(Figure 1) and 10-methoxycamptothecin from the stem wood
of Xi Shu. Later, Hsu and co-workers (1977) and Lin and
others (1979) isolated Il-hydroxycamptothecin, 11-
methoxycamptothecin, and 20-deoxycamptothecin from the
fruit. Recently, Lin and Cordell (1989, 1990a, b) isolated 22-
hydroxyacuminatine and 19-hydroxy-mappicine and
pyridoindole alkaloid 19-0-methy-langustoline from the fruit.
In addition, quercetin, kaempferol, trifolin, and gallic acid
have been isolated from Xi Shu (Tien et a1. 1977).
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FIGURE 1. Chemical structure of camptothecin and its main
analogs.
CPT and its derivatives are quinoline alkaloids with a
novel ring system. But its lack of significant basicity causes it
to behave as a neutral molecule so that CPT is not an alkaloid
in the usual sense of the definition. Water insolubility and
high toxicity of CPT were major problems in clinical trials. In
order to overcome the side effects obtained with the sodium
salt of CPT in the early 1970s, a number of water-soluble
derivatives have been synthesized recently. Two of these
derivatives, topotecan (TPT) and irinotecan (CPT·ll) are
water-soluble, they are in clinical trials and their
chemotherapeutic efficacy is promising. HCPT is the basis for
making both TPT and CPT-ll, and that HePT can be made
readily by synthesis from CPT. Another derivative, 9-
aminocamptothecin (9-AC) is not soluble in water, and it is
also being introduced into clinical trials. 9-Ac can be prepared
either by total synthesis or from CPT.
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The procedure for synthesis of CPT is rather complicated,
and the first total synthesis was reported in 1971 in the United
States by Stork and Schultzin (1971). The total synthesis of
more complex HCPT and 10-methoxycamptothecin was first
announced in 1977 in China (Cai et a1. 1977). In 1980, Wall
and associates greatly improved the synthesis of CPT and
prepared a number of analogs (Wani and Wall 1980). Wall
and co-workers reviewed the synthesis and structure activity
of CPT analogs (Wall and Wani 1993, Wall et a1. 1993). Many
syntheses rely on the Friedlander quinoline synthesis to
construct ring B. Although much synthetic work has been
reported, most of the syntheses are not commercially
attractive.
Several major international drug agents are actively
working with camptothecins. NCr is conducting studies with
9·AC. Daiichi Pharmaceutical Company and Yakult Honsha
Company in Japan are developing CPT-ll. SmithKline
Beecham Pharmaceutical Company in the United States is
producing TPT. In addition, Glaxo Pharmaceutical Company
in the United States, at one time, had the worldwide rights to
develop and market CPT analogs for the Research Triangle
Institute.
Literature Records
Historical research interest in camptothecins and Xi Shu is
clearly recorded in the scientific literature. Totally, 1,113
publications on camptothecins and Xi Shu including books,
articles, dissertations, symposium reports, and government
documents between 1846 and 1993 have been located and are
cited in the Bibliography. 928 publications or 83.4% of the
total publications are in English, 89 in Japanese (8.0%), 88 in
Chinese (7.9%), and 8 in other languages (0.7%) including
Russian, Korean, Italian, French, German, and Turkmen.
However, about 40% of the total studies were conducted
outside the United States and many of these are published in
English.
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FIGURE 2. Description and illustration of Xi Shu in Zhiwu Mingshi
Tukao by Wu in 1848.
The first appearance of Xi Shu was in a Chinese book
Zhiwu Mingshi Tukao (m4m~.Il~) (Illustrated
investigation of the names and natures of plants) in 1848 (Wu
1848). This Chinese herbal book briefly described
morphology and habitat, but not uses (Figure 2). It recorded
that Han Lian (Xi Shu) grows in the western mountains in
Nanchang (in Jiangxi), has reddish brown bark, green stems,
leaves like those on no-floral shoots of paper mulberry,
fruiting in the fall, with tens of fruits together in a ball about
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FIGURE 3. Number of publications on camptothecins and Xi Shu,
1848-1994 (1,113 publications were recorded from 1848 to 1993
with an additional 200 publications expected in 1994. The literature
search covers Chemical Abstracts, Biological Abstracts, AGRICOLA,
CAB, Life Sciences Collection, Pascal, and MEDLINE through STN
International, DIALOG, and others).
the same as the water bean in size, and which resembles qiu
(a fur ball for a traditional Chinese game).
Only 25 publications from 1848 to 1965 can be found
about Xi Shu and all are concerned with botany. Since the
isolation of CPT in 1965, publications have shown two active
periods (Figure 3). The first period was from 1971 to 1974,
which averages about 28 publications each year (total 110
items or about 9.9% of a total of 1,113 publications) and the
research had expanded to inelude a wide variety of topical
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areas connected to botany, ecology, chemistry, pharmacology,
and clinical trials. However, publications then decreased until
the late 19808 after the finding of toxicity constraints of CPT.
During the period from 1975 to 1986, the research was limited,
especially in the United States, because the CPT was found
very water-insoluble and toxic. During these 12 years, only
209 items were published and the studies had been largely
conducted in the field of chemistry, with 36% in Chinese and
Japanese. The novel mechanism of action of CPT and analogs
found in 1985 and extensive clinical trials in China and Japan
has led to renewed research interest and produced the second
peak publication period in the late 19808 and early 1990s.
During the 1987-1993 period, 730 publications were published
(65.6% of the total publications) with an average of about 104
items each year.
3. MECHANISMS OF ACTION
OF CAMPTOTHECINS
Camptothecins have exhibited a broad spectrum of anti-
tumor activity both in vitro and in vivo. AB stated by Dr. B. C.
Giovanella of the Stehlin Foundation for Cancer Research in
Houston, camptothecins are the most promising drugs that
have ever been found. In sufficient quantity, they are toxic to
many plants, insects, and animals. Moreover, camptothecins
show potent activity against many DNA viruses and some
RNA viruses such as retroviruses. The physiological action of
camptothecins is unique. Unlike taxol and other anti-tumor
agents, camptothecins stabilize the cleavable complex
between eukaryotic DNA and enzyme topoisamerase I (topa I,
Hsiang et a1. 1985). The mechanisms of action of
camptothecins have stimulated great research interest.
Initial experiments suggested that the principal effect of
CPT on cultured mammalian cells is its immediate and potent
inhibition of DNA and RNA biosynthesis (Horwitz et a1. 1971,
Kessel 1971, Kessel et a1. 1972, Abelson and Penman 1972,
1974). It was observed that CPT causes shortened RNA chains
but the effect is rapidly reversible when the drug is removed
(Abelson and Penman 1972). The drug affects the
biosynthesis of ribosomal RNA more than other types of
cellular RNA (Cai and Hutchinson 1983). The inhibition of
DNA synthesis, on the other hand, is only partially reversible
upon drug removal (Horwitz et a1. 1971, Kessel et a1. 1972).
CPT is a much stronger inhibitor of DNA synthesis than RNA
synthesis in human lymphocytes stimulated by phytohe-
magglutinin (Gallo et a1. 1971). Also, it was reported that CPT
inhibits the replication of DNA viruses but not RNA viruses
(Becker and Olshevsky 1973, Horwitz 1975). Thus, both
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cellular and viral observations lead to the conclusion that the
cytotoxic effect of CPT results from a disruption of the normal
function of DNA. However, CPT itself does not cleave either
purified DNA polymerase or purified RNA polymerase
(Horwitz et aI. 1971). Since CPT does not affect the enzymes
involved in DNA biosynthesis, the inhibitory effect of CPT is
believed to be the result of some action on the template
function of DNA rather than on the enzyme activity of DNA
polymerases (Hutchinson 1981, Cai and Hutchinson 1983). It
was believed that the molecular mechanism of action of CPT
included a DNA-binding component and a mechanism for
covalent bond breakage in polydeoxyibonucleotides. In 1985,
however, Hsiang and his colleagues found that CPT has no
effect on DNA alone, but the addition of CPT to a solution
containing nuclear enzyme topo I and DNA results in nicking
of the DNA (Hsiang et a1. 1985). This important finding
stimulated further investigations on mechanism of action of
camptothecins. Now it is commonly recognized that the DNA
enzyme topo I is the main target of camptothecins inhibiting
cells and DNA viruses. CPT and its analogs are one of few
inhibitors of topo I possessing known anti-tumor activity.
Thus, recognition of this novel mechanism of action has led to
great interest in additional clinical tests of CPT and its
analogs.
DNA topoisomerases (I and II) are found in the nuclei of
all eukaryotic cells and playa major role in DNA replication
and transcription (Horwitz and Horwitz 1973), and each is
probably encoded by a single gene (Wang 1985). They are
highly active in cells that are metabolically active, especially
in those from rapidly dividing tissues. Also, topo I is active in
replication of retroviruses such as HIV, EIAV, and Mo-MuLV
that cause many severe diseases in humans and animals
including AIDS, but it differs in character from that in cells
(Priel et a1. 1991b). The function of these enzymes appears to
be to facilitate the relaxation, unwinding, controlled cleavage,
and rejoining of the DNA helix during replication and
transcription (Figure 4). Without topoisomerasea, DNA
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FIGURE 4. Mechanism of the inhibition of topo I by camptothecins
(redrawn from Slichenmyer et al. 1993). Interaction of topo I with
advancing replication forks results in DNA double-strand breaks.
CPT, which is unable to bind to free topo I, binds to the tapa I-DNA
adduct and thus inhibit DNA synthesis.
would be unable to participate in many biochemical reactions
and would degenerate into an irretrievable tangle.
Topoisomerase I can cleave only a single DNA strand whereas
type II cleaves both strands of the helix. The enzyme forms a
protein bridge across the ends of the divided DNA molecule
until continuity is restored, but camptothecins stabilize the
DNA/protein complex so that the normally rapid process of
strand division, disentangling, and rejoining is arrested at mid-
stage (Editorial 1990). The mid-stage arrest appears to
activate endogenous nucleases so that the cell does not
merely stop growing-its DNA is degraded and it dies.
Topoisomerase II (topo II) relieves torsional strain in
replicating DNA by causing and then repairing double-
stranded breaks (Saltz et a1. 1993). It requires ATP, which
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may offer more targets for inhibitors' action. Therefore, a
number of anti-tumor agents stabilize the formation of a
cleavable complex between DNA and topo II. Topo I is a
monomeric 100-kDa polypeptide encoded by a single-copy
gene (Liu and Miller 1981, Juan et a1. 1988). It causes a
single-stranded DNA break, permits the passage of the intact
strand through the break, and then reseals the broken strand.
It does not require a cofactor. There are few tapa I inhibitors.
Two other recently found topo I inhibitors that have anti-
tumor activity are B-Lapachone (Li et a1. 1993) and intoplicine
(Eckardt et a1. 1994). But unlike camptothecins, these two do
not stabilize the cleavable complex between DNA and tapa I.
Camptothecins are the only topo I inhibitors whose ability to
stabilize the cleavable complex has been well characterized.
CPT and its analogs inhibit topa I catalytic activity and
bind the topo I-DNA adduct. The observed DNA single-strand
breaks observed with addition of CPT represent the nicks that
form when CPT stabilizes covalent adducts between genomic
DNA and enzyme tapa I (Slichenmyer et a1. 1993). At present,
the interaction between CPT and the tapo I-DNA complex
seems central to the cytotoxicity of CPT and its analogs. But
the nature of the binding between CPT and the tapa I-DNA
adducts remains unclear.
Structure-activity studies indicate that substitutions at the
9- and IO-positions of CPT generally increased tapa I
inhibition (Hsiang et aI. 1989, Kingsbury et a1. 1991, Pommier
et al. 1991), It was observed that 104 hydroxycamptothecin
(HCPT) is more potent than CPT (Shanghai Institute of
Materia Medica 1978, Zeng 1982, Han 1988) and SN-38 (7-
ethyl-lO-hydroxycamptothecin) is remarkably more potent
than CPT and HCPT (Tanizawa et a1. 1994). Therefore, the 7-
ethyl group appears to increase the drug potency. However,
this increased potency does not appear to result from the
induction of more cleavage sites but from the great stability of
individual sites (Tanizawa et a!. 1994). It is well established
that in solution at physiologic pH, CPT and its analogs exist in
an equilibrium between the closed-ring lactone form and the
open-ring carboxylic acid form. The cleavable complexes
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between DNA and tapa I result from a constant equilibrium
between such drug stacking (Jaxel et a1. 1991, Pommier et a1.
1993) and drug dissociation (Covey et a1. 1989). Once
administered, the drugs are rapidly hydrolyzed in plasma to
the open-ring form, producing a complete loss of biological
activity (Wani et a1. 1987, Kuhn et a1. 1990, Rowinsky et a1.
1992). The full therapeutic utility of camptothecins is limited
by the aqueous instability of the lactone ring moiety, and
reduction of drug dissociation would be expected to increase
the persistence time of cleavable complexes and their overall
frequency. The 7-ethyl and 10-hydroxyl groups seem to slow
the drug dissociation from the cleavable complexes (Tanizawa
et a1. 1994). Also, Burke and co-workers (1992) recently
found that Iiposome-bound CPT is stable. This suggests that
liposomes may serve as an effective drug delivery system for
soluble camptothecins, conserving its lactone ring and the
anti-tumor activity. The stabilization results from penetration
of CPT's lactone ring into the bilayer, isolating it from solution
(Burke et a!. 1992).
CPT and analogs inhibit not only cellular but also viral
tapa 1. lO-Methoxycamptothecin is more effective than CPT as
an inhibitor of DNA viruses (Tafur et a1. 1976).
Camptothecins therefore represent a new direction in virus
diseases chemotherapy. The mechanism of anti-viral action of
camptothecins is discussed in detail in chapter 5.
4. PRECLINICAL AND CLINICAL
TRIALS OF CAMPTOTHECINS
IN CANCER TREATMENT
The development of new anti-tumor agents is a complex,
stepwise process proceeding from discovery to demonstration
of anti-tumor activity in preclinical tests and evaluation of
normal tissue toxicity prior to initiation of clinical trials. The
major purpose of phase I clinical trials is to determine the
toxic effects of the agent and the recommended phase II
dosage. Thus, phase I trials address an estimation problem
rather than the testing of a hypothesis (Ratain et a1. 1993).
Phase II trials are generally studies with no control group that
are aimed at estimating the anti-tumor efficacy of a new agent
in a particular disease.
CPT and its analogs belong to a group of anti-tumor
agents with unique mechanisms of action: stabilizing the
cleavable complex between eukaryotic DNA and enzyme
topoisomerase I. CPT and some analogs (HCPr, TPT, CPT-ll,
and 9-AC) are in clinical trials in China, Japan, United States,
and Europe and their chemotherapeutic efficacy appears
promising. The drugs are usually intravenously injected.
Oral CPT is being used both in its traditional formulation in
China and Japan and in a recently opened phase I trial in the
United States. In the United States, however, phase II
evaluations have been limited relative to China and Japan. At
present, at least 10 cancer hospitals are funning clinical trials
of camptothecins in the United States. Since camptothecins
are experimental drugs, FDA requires that camptothecins be
given at extremely low doses in clinical trials. In general,
camptothecins show promising antitumor activity in clinical
trials. As Wall points out, however, there are many
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problems, particularly for the water-insoluble analogs, but
these problems are being solved (Wall 1993).
Camptothecin (CPT)
[n solution at physiologic pH, CPT (NSC-I00880) exists in
an equilibrium between the closed-ring lactone and the open-
ring hydroxy acid form. The closed-ring form is favored at
lower pH. Because CPT lactone is extremely insoluble in
aqueous solutions, the readily water-soluble sodium salt of
the open-ring hydroxy acid was utilized in the initial clinical
trials. Animal tests had revealed that the sodium salt was 10-
fold less potent than CPT lactone, although it had a similar
spectrum of activity against murine tumors (Wani et a1. 1980).
Dr. Beppino C. Giovanella and his colleagues at the Stehlin
Foundation for Cancer Research, Texas, found that a total 23
out of 23 human cancers (lymphoma, colon, lung, breast,
melanoma, ovary, pancreas, and stomach) growing in nude
mice responded to CPT.
Three intravenous administration schedules were
evaluated during the phase I trials in the United States in the
early 1970s. At the 1970 annual meeting of the American
Association for Cancer Research, Dr. J. A. Gottlieb and co-
workers of the NCr reported on results of administering the
water soluble sodium salt of CPT to 17 adults with various
types of cancer with single doses of sodium CPT (0.5-10 mg/kg)
every 2-4 weeks (Gottlieb et a1. 1970). Of nine patients with
advanced cancer of the intestine and rectum, four achieved
tumor reductions greater than 50%; in four others tumor
masses decreased 25 to 50%. One patient with melanoma
experienced greater than 50% reduction in tumor nodules; one
adult with lung cancer and another with acute myelocytic
leukemia had from 25 to 50% decreases in tumor mass. Later,
F. M. Muggia and co-workers (1972) reported that there were
two partial responses in 10 patients with gastric
adenocarcinoma and non-small-cell lung tumors after
treatment once daily for 5 consecutive days every 3 weeks. In
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a phase II trial, only two patients showed partial responses in
61 patients with adenocarcinomas of the gastrointestinal tract
(Moertel et a1. 1972). Also, unfortunately, the toxic effects of
CPT sodium salt were observed in both phase I and II trials.
These include myelosuppression, gastrointestinal toxicity,
hemorrhagic cystitis, and alopecia at the higher dose levels
(Gottlieb et a1. 1970, Muggia et a1. 1972, Schaeppi et al. 1974).
These initial clinical results using the sodium salt of CPT were
disappointing, and clinical interest in CPT languished from
1972 to 1988 in the United States (Schultz 1973, Cai and
Hutchinson 1983, Wall 1977, 1993). During the late 1970s and
early 1980s, CPT was used in clinical treatment of cancer only
in China.
In China, clinical trials started in 1968 in the Chinese
Academy of Medical Sciences, and responses were observed in
those patients with leukemia (Lin et a1. 1977). In China, the
sodium salt of CPT was originally used. However, studies on
the improvement of CPT formulations were performed at the
Shanghai Institute of Materia Medica soon after the sodium
salt was found to be toxic. The trials showed that CPT
prepared in particle sizes less than 1 Ilm were quite effective
in animal experiments. Clinical trials with 450 patients in
Guangxi Medical College (Zeng 1982) confirmed this result.
Although the original CPT sodium salt solution was
reported to possess very low activity against primary liver
cancer, the non-sodium CPT suspension was considered to be
effective. After treatment, 18.2-49.0% of the patients who
originally could not be treated by surgical operation became
suitable for surgery (Zeng 1982). Similarly, nausea, vomiting,
and hematuria occurred in 64% of the sodium salt treated
group, but only 10% of the suspension treated group. Later,
Wall and others further confirmed that the CPT sodium salt
has only one-tenth the potency of CPT in one anti-tumor
assay (Hutchinson 1981).
In May 1992, the Stehlin Foundation for Cancer Research
in Houston began its clinical study of CPT in a pill form.
Major responses have been seen in breast and prostate
cancers, lymphoma, and malignant melanoma (Stehlin
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Foundation for Cancer Research, 1993).
In the United States, phase II evaluations were limited to
trials in patients with advanced gastrointestinal
adenocarcinomas (Moertel et a1. 1972) and malignant
melanoma (Gottlieb and Luce 1972). However, response rates
were lower than in phase I trials.
Recently, CPT has been studied using the closed lactone
ring and found very active against human cancer xenografts
(Giovanella et a1. 1991). Phase I trials of CPT have been
completely successful demonstrating tolerate toxicity at
effective doses administered orally (Stehlin et a1. 1994).
Presently, CPT is undergoing extensive phase I trials and
phase II trials in breast cancer.
lO-Hydroxycamptothecin (HCPT)
10-Hydroxycamptothecin (HCPT) was isolated by Wani
and Wall (1969). Later they found that HCPT was the most
active compound in the series and was more active than CPT
in both L1210 and P388 leukemia life prolongation assays
(Wani et a1. 1980, Wall 1993). HCPT is a water-insoluble
agent, but its potent anti-tumor activity stimulated synthetic
efforts of TPT and CPT~l1 water-soluble analogs of HCPT by
SmithKline Beecham and a Japanese pharmaceutical
company.
The water-soluble salt of HCPT was first clinically used in
China (Cai and Hutchinson 1983). The studies showed that
the salt HCPT is more active and less toxic than the sodium
CPT, especially for head and neck cancer, liver carcinoma,
leukemia, gastric cancer, and urinary bladder carcinoma
(Shanghai Institute of Materia Medica 1978, Zeng 1982, Han
1988). At the Shanghai Institute of Materia Medica, it was
found that the disodium salt of HePT exhibited an obvious
inhibitory action on both ascites and solid tumors, such as
Ehrlich ascites carcinoma, ascetic reticule cell sarcoma,
Yoshida sarcoma, sarcoma S37, and Walker carcinoma. In the
phase II clinical trials 63 cases were evaluated. The effective
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rate of reduction in tumor activity was 42.1% (8 of 19 patients)
in the treatment of liver cancer and 39.8% (11 out of 28
patients) in head and neck cancers (Zeng 1982). It was
reported that the sodium HCPT inhibited the clonogenicity of
KB cells and exhibited DNA damage in L1210 cells (Wang et
a1. 1986). Cai and Hutchinson (1983) stated that HCPT had the
best activity against lung tumor among camptothecins. The
toxicity of the sodium salt of HCPT was much less than that
caused by the sodium salt of CPT, especially with respect to
irritation of the urinary tract.
Topotecan (TPT)
Topotecan (TPT), 9-dimethylaminomethyl-l0-hydroxy-
camptothecin (SK&FI04864, SK&FI04864A, or NSC609699),
previously called hycamptamine, is a semisynthetic analog of
HePT. It was identified by R. K. Johnson and co-workers at
SmithKline Beecham in 1989 as a water-soluble agent with a
broad spectrum of anti-tumor activity (Johnson et a1. 1989).
The structure of TPT incorporates a stable basic side chain at
the 9 position of the A-ring of HCPT. This permits the
formation of a hydrochloride salt with greatly increased
aqueous solubility over that of the parent compound and thus
reduces some toxic effects while still maintaining preclinical
activity.
TPT has been shown to posses considerable anti-tumor
activity in vitro against a large number of murine leukemias
and transplantable solid tumors, including P388 leukemia,
L1210 leukemia, B16 melanoma, M-5076 reticulum cell
sarcoma, Lewis lung carcinoma, central nervous system
tumor, and HT-29 human colonic adenocarcinoma (Saltz et a1.
1993, Friedman et a1. 1994).
A number of TPT single-agent studies were made in phase
I trials. Major responses to TPT have been observed in
patients with ovarian cancer (Rowinsky et a1. 1992a, b), non-
small-cell lung cancer (Rowinsky et al. 1992a, b, Verweij et a1.
1992), small-cell lung cancer (Verweij et a1. 1992), esophageal
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cancer (Sirott et al. 1991), and colorectal cancer (Haas et al.
1992) as well as acute leukemia (Beran et al. 1992). The
principal dose-limiting toxic effect on most schedules is brief,
noncumulative neutropenia, occurring either alone or with
thrombocytopenia. Other side effects such as nausea,
vomiting, rashes, diarrhea, and alopecia were usually mild
and rare at TPT doses associated with severe
myelosuppression (Slichenmyer et al. 1993). Bladder toxicity
has not been reported following administration of topotecan
(Hawkins 1992). The maximum tolerated dose was highly
schedule dependent, and less drug was tolerated when given
by continuous infusion. However, prior cytotoxic therapy
decreased the ability of patients to tolerate TPT. Thus, L.
Saltz and co~workers (1993) suggest that the doses of TPT
recommended for use in phase II clinical trials in solid tumors
are 1.5 and 1.25 mg/m2 of surface skin area daily in previously
untreated and previously treated patients, respectively.
Based on observed rates of recovery from myelosuppression,
treatment should be possible on a 21-day cycle.
Phase II trials have begun in patients with a wide range of
solid tumors (Slichenmyer et a1. 1993). Testing using daily
administration of 1.5 mg/m 2 for 5 days is currently underway
(Hawkins 1992).
Irinotecan (CPT-II)
Irinotecan, 7-ethyl-lO-[4-( I-piperidi no)-l-piperidino]
carbonyloxycamptothecin (NSC616348) is another water
soluble analog of HCPT. It was initially developed in Japan
by Kunimoto and his colleagues (1987). Unlike CPT and TPT,
CPT-ll has little inherent anti-tumor activity in vitro
(Slichenmyer et al. 1993). Instead, CPT-ll is a pro-drug that
undergoes de-esterification in vivo to yield SN-38 (7-ethyl-l0-
hydroxycamptothecin), which is approximately lOO-fold more
potent than the parent compound against tumor cells in vitro
(Kaneda et al. 1990, Kawato et al. 1991a). Therefore, the
clinical activity of CPT-ll may strongly depend on its
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hydrolysis to SN-38 (Tanizawa et al. 1994).
CPT-ll has shown substantial activity in vivo against a
variety of tumor xenografts when administrated by
intraperitoneal, intravenous, or oral routes (Kunimoto et a1.
1987). The agent was more active than other analogs over a
broad dose range. It demonstrated activity against some
human tumor xenografts, including colon adenocarcinoma Co-
4, mammary carcinoma MX-1, gastric adenocarcinomas St-15
and SC-6, as well as squamous cell lung carcinoma QG-56
implanted subcutaneously in nude mice (Kawato et a1. 1991b).
It also has anti-tumor activity against rat Walker 256
carcinoma (Furuta et al. 1988).
Phase I clinical trials have been performed in Japan and
more recently in the United States and Europe. Major
responses have been observed in patients with non-smaIl-cell
lung cancer (Negoro et a1. 1991), colorectal cancer (Rowinsky
et a1. 1992a, b, Gandia et al. 1992, Sasaki et a1. 1994), cervical
cancer (Rowinsky et a1. 1992a, b), and breast cancer (Clavel et
a1. 1992). In contrast to TPT, CPT-ll produces prominent
nonhematologic toxic effects at myelosupressive doses.
Diarrhea is a serious side effect occurring on virtually all
schedules of administration studied to date. On schedules
where larger individual doses are administrated, diarrhea
begins during or immediately after a 60-90 minute infusion of
CPT-ll (Slichenmyer et a1. 1993). When CPT-ll is given by
bolus or short-duration IV infusions, leukopenia occurs more
frequently than diarrhea (Ohe et a1. 1992, Takeuchi et a1.
1991a, b). Thus, diarrhea is the dose-limiting toxic effect,
depending on the schedule of administration (Ohno et a1.
1990, Burris et a1. 1992b, Ohe et a1. 1992). Using a single
administration every 3 weeks, the maximum tolerated dose
reported was 250 mg/m 2 (Ohno et a1. 1990) and 290 mg/m2
(Burris et a1. 1992b, Rowinsky et a1. 1992a, b), with diarrhea
as a dose-limiting toxicity in addition to neutropenia. The
schedule was not chosen for phase II studies, because a
weekly schedule allowed a higher dose intensity (Abigerges et
a1. 1994). Recently, D. Abigerges and others (1994) used a
loperamide protocol to control diarrhea that clearly allowed
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the administration of higher dose levels of CPT-ll (given
every 3 weeks, the maximum tolerated dose was 750 mg/m2).
Phase II trials of CPT-ll have been performed in Japan.
Most trials in adults with solid tumors have evaluated CPT-ll
administered on a weekly schedule, whereas most studies for
leukemia and lymphoma evaluated CPT-ll administered over
60-90 minutes for either 3 consecutive days every week or 5
consecutive days every 3-4 weeks (Slichenmyer et al. 1993).
CPT-II has demonstrated activity against a variety of tumors,
including colorectal cancer (46% response rate in patients
with prior chemotherapy, Shimada et al. 1993), ovarian cancer
(21% response rate in patients with prior chemotherapy,
Takeuchi et al. 1991b), cervical cancer (43% response rate
with some complete responses, Takeuchi et al. 1992), non-
small-cell lung carcinoma (31.9% response rate in patients
with no prior chemotherapy, Fukuoka et al. 1992), and small-
cell lung cancer (33-50% response rate, Negaro et al. 1991,
Masuda et al. 1992) as well as lymphomas and leukemias
(Ohno et al. 1990, Tsuda et al. 1992). Side effects of CPT-II
during phase II are similar to those observed during phase I
studies. Also, pulmonary toxicity has been observed for
patients with lung cancers (Fukuoka et al. 1992).
9-Aminocamptothecin (9-AC)
9-Aminocamptothecin (NSC603071) is a synthetic analog
of CPT and not soluble in water. 9-AC was first investigated
by Wall and Wani at the Research Triangle Institute. Wani et
al. (1987) showed that 9-AC has potent activity in the L1210
mouse leukemia. The animal tests show that 9-AC is a potent
anti-cancer agent, highly effective against three lines of
human colon cancer (Giovanella et al. 1989). It is much more
effective in colon cancer than fluorouracil (5-FU), doxorubicin,
or several other cytotoxic drugs. The overall drug toxicity was
low and allowed for repeated courses of treatment. Its high
efficacy, however, is not completely understood. This drug
has been i.ntroduced into clinical trials because it exhibits
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strong antitumor activity against solid tumor xenografts
(Giovanella et a1. 1989, Potmesil et a1. 1993). It is in clinical
trials in patients with a variety of cancers at the National
Cancer Institute and other facilities.
In addition, other analogs of CPT show anti-tumor activity.
According to Cai and Hutchinson (1983), 9-
methoxycamptothecin showed marked activity against
leukemia P388, but only fair activity in L1210. 10-
Methoxycamptothecin is somewhat less active than CPT (Wall
1993). ll-Methoxycamptothecin was found also to have anti-
tumor activity (Zeng 1982). More recently, Giovanella and
associates found that 9-nitrocamptothecin, which is much
easier to prepare and non stable derivative of 9-AC also
possess very high anti-cancer activity against human cancer
xenografts in nude mice (Pantazis et a1. 1993). It has also
been demonstrated that 9-nitrocamptothecin is transformed
into 9-AC when administered to mice, dogs, and humans (Hinz
et al. 1994).
In summary, camptothecins are anti-cancer agents with
unique mechanisms of action and great chemotherapeutic
efficacy. Recently, A. Tanizawa and co-workers (1994)
evaluated CPT and some derivatives presently in clinical trials
in HT-29 cells and in isolated nuclei. It was found that both
the cytotoxic potency and the potency of the compounds to
induce protein-linked DNA breaks are in the following order:
SN-38 > CPT> 9-AC > TPT > CPT-H. SN-38 is the most
potent compound and 9-AC and TPT less active than CPT in
vitro. The effect of CPT-ll is minimum.
However, Wall and associates found that 9-AC is always
more potent than CPT, both in cytotoxicity and, even more
importantly, in the inhibition of topoisomerase I (M. E. Wall,
pers. comm., September 1994). According to T. D. Moore of
NCI, CPT-ll has the greatest activity in colon cancer, TPT has
the greatest activity in small-cell lung cancers, some activity
in ovarian cancer, and very exciting activity in several
pediatric cancers, and 9-AC should work in all these disease
sites (Jenks 1994).
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Because camptothecins work at specific phases of the cell
cycle, they are more effective when administered continuously
than intermittently (Slichenmyer et a1. 1993, Tanizawa et a1.
1994, Jenks 1994). The longer you retain drugs, the longer
breaks occur in the DNA, according to J. Eckardt at the
University of Texas Cancer Therapy and Research Center in
San Antonio (Jenks 1994). In certain instances, according to T.
Pantazis, cancer cells have been able to evade CPT's toxicity
by developing different metabolic routes, but the cells then
become ultrasensitive to other drugs to which they were not
sensitive before they were exposed to camptothecin (Stehlin
Foundation for Cancer Research, 1993). Also, because of its
unique mechanism of action and lack of bone marrow
depression, CPT can be used in combination with other drugs
that have different mechanisms of action (Stehlin Foundation
for Cancer Research, 1993). For instance, John Eckardt and
his colleagues at the University of Texas Cancer Therapy and
Research Center in San Antonio recently used TPT and
cisplatin in patients with untreated non-smaIl-cell lung
cancer. The working hypothesis is that the best way to effect
a response is first to damage the DNA with non~cell-cycle­
specific drug cisplatin and then bring in the TPT, a cell-cycle-
specific drug, whose inhibitory effect on cell repair causes
cells to die (Jenks 1994). They found that TPT enhanced the
ability of the cisplatin to kill tumor cells, but the reverse is
not true. R. C. Lilenbaum of the Cancer and Leukemia Group
B in Lebanon, New Hampshire used taxol and TPT together in
patients with a variety of advanced solid tumors. Because
taxol in essence freezes the cell, and TPT inhibits DNA repair,
the two will act at different phases of the development to
destroy tumor cells (Jenks 1994).
5. POTENTIAL ANTI-VIRAL
ACTIVITY
OF CAMPTOTHECINS
Camptothecins, Potential Anti-viral Drugs
Viruses are minute packages of a single type of nucleic
acid, either DNA or RNA surrounded by a protein coat and
sometimes a lipid membrane. There are thus two different
categories of viruses: DNA viruses and RNA viruses, and
hundreds of kinds of viruses, many of which cause plant and
animal diseases (Postlethwait et al. 1991).
DNA viruses include 6 families: Hepadnaviridae,
Papovaviridae, Adenoviridae, Herpesviridae, Poxviridae, and
Parvoviridae. The hepadnaviruses cause hepatitis, which may
progress to cirrhosis and primary hepatocellular carcinoma.
Papillomaviruses of the family Papovaviridae cause human
warts and some species are oncogenic while polyomaviruses
commonly produce inapparent infection. Human
adenoviruses are associated with infections primarily of the
respiratory tract.
RNA viruses have 13 families (White and Fenner 1986).
Retroviridae (re = reverse, tr = transcriptase) is a large family.
The subfamily Oncovirinae includes the human T-cell
leukemia virus (ATLLV), which causes leukemia carcinoma.
The subfamily Lentivirinae of retroviruses includes causative
agents of severe diseases in humans and animals, such as
human immunodeficiency virus (HIV), equine infectious
anemia virus (EIAV), Friend spleen focus forming virus
(SFFV), and Moloney murine leukemia virus (Mo-MuLV).
HIV causes the acquired immune deficiency syndrome (AIDS)
in humans. Other retroviruses cause animal diseases such as
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erythroleukemia, lymphoma, viremia, anemia, tissue injury.
and erythrocyte destruction.
As early as in 1970s, CPT was found to inhibit the
replication of DNA viruses such as adenovirus, vaccinia virus
(Poxviridae), and herpesvirus, and to have no effect on the
replication of poliovirus, an RNA virus (Becker and Olshevsky
1973, Horwitz 1975). 10-Methoxycamptothecin was found to
be about eight times more potent than CPT as an inhibitor of
herpesvirus (Tafur et al. 1976). In the 19708, it was believed
that CPT was active only on DNA viruses (Cai and Hutchinson
1983), with DNA topoisomerase I being the primary target for
the inhibitory role of CPT in DNA replication (Liu 1989,
Bjornsti 1991, Champoux 1992). Deng and co-workers
recently evaluated the effects of selected DNA repair
inhibitors on the an increased frequency human
cytomegalovirus (HCMV)-induced chromosome aberrations in
human peripheral blood lymphocytes (Deng et al. 1992).
They found that CPT is a significant agent causing frequency
of HCMV-induced chromosome damage. In addition, recent
studies have demonstrated that at very low concentrations,
CPT is able to block replication of RNA viruses (retroviruses)
in infected cells (Priel et a1. 1991a, 1991b, 1993, Kerr et al.
1993, Li et a1. 1993, 1994a, b).
CPT inhibited HIV replication in acute infection of H9
cells at a high efficacy (>90%) at noncytotoxic doses (Priel et
al. 1991a). The study of C. J. Li and co-workers (1993) shows
that TPT potentially inhibits both acute and chronic infection
of HIV-l. It is also found that CPT inhibits the replication of
EIAV in chronically infected CF2Th cells (Priel et a1. 1991b).
According to E. Priel and co-workers (l991b), continuous
exposure of these cells to the drug for 52 days revealed 85 to
92% inhibition of virus production. Recently, it was observed
that CPT, administrated together with the virus (NFFV or Mo-
MuLV) or 1 or 2 days after virus injection, prevented the onset
of the disease in mice (Priel et a1. 1993). No effect on the
viability or growth rate of the cells was detected in drug
administration according to these studies. Presently, some
anti-viral agents block retroviral replication only at early
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stages of the viral infection process; whereas, other agents
suppress HIV expression only in chronically infected cells (Ho
et a1. 1985, Priel et a1. 1991b). However, CPT acts as an anti-
viral drug at both levels, inhibiting retroviral replication in
both acutely and chronically infected cells. It thus has
potential advantages as a legitimate remedy for the treatment
of retroviral diseases over other drugs.
CPT and its analogs have an inhibitory effect not only on
HIV-1, but also on other viruses associated with AIDS.
Human polyomavirus (JCV, Papovaviridae), is the causative
agent of progressive multi-focal leukoencephalopathy, a
subacute demyelinating disease of the central nervous system.
This disease occurs in association with a defect in cell-
mediated immunity. According to the study of D. A. Kerr and
co-workers (1993), pulse-treatment of glial cells with non-
toxic levels of CPT specifically blocked JCV viral DNA
replication with no inhibitory effect on host transcription and
translation processes as examined by viral gene expression in
the transfected cells.
Mechanism of Action
It is essential to know the life cycle of a virus in order to
understand the mechanism of the anti-viral action of a drug.
Viruses are not cells, and they are completely dependent
upon their cellular hosts for the machinery of protein
synthesis and energy production. They infect both
prokaryotic and eukaryotic cells by attaching to the plasma
membrane and then allowing their DNA or RNA to enter the
cell. Once inside, the viral genes take over the cell's protein-
synthesizing machinery for viral replication. The speed of
viral reproduction is astounding. In 24 hours, one virus
particle could generate enough particles to fill the universe
(Postlethwait et a1. 1991). In nature, however, reproduction is
always limited by the availability of cells, since viruses lack
the machinery for replication.
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Some anti-viral drugs prevent certain viruses from
shedding their coats so that the viruses cannot infect cells.
Some drugs (e.g., interferon) prevent cells from replicating
viruses whereas others block the activity of the viral enzymes.
Because DNA enzyme topo I is the main target of
camptothecins, it is understandable that camptothecins show
potent inhibitory effects on the replication of DNA viruses.
Surprisingly, however, camptothecins also inhibit the RNA
viruses such as retroviruses that do not contain DNA.
Although the DNA enzyme topo I is active in the viral core of
ErAV and is at least actively associated with HIV and Mo-
MuLV, it seems reasonable that topo I may be the main, if not
the exclusive, target of CPT (Priel et al. 1991b, 1993). But the
mechanism of action of camptothecins on RNA viruses is
possibly more complicated.
It is well established that the hallmark of infection by
HIV-l and other retroviruses is formation of provirus through
reverse transcription, integration, and then transcription from
proviral DNA. Transcription of this proviral DNA is an
essential step for viral replication, and controlled by the long
terminal repeat (LTR). HIV-l LTR has recently become a
promising site for ant-viral action (Li et al. 1994b). C. J. Li and
co-workers (1993, 1994a) found that CPT and TPT inhibit HN-
LTR activity induced by viral transactivator (Tat) and
cytokinesis. The exact mode of action of the inhibition is still
unclear. One possibility is that DNA topo I influences
Tat/TAR-mediated transcription by selectively interacting with
TatJTAR or their associated protein, and that DNA topo I is the
CPT-inhibited step here. However, C. J. Li and co-workers
(l994a) believe that the inhibition by CPT of HIV-l long
terminal repeat (LTR) is probably independent of its
inhibition of DNA topo I, and that the target may be a novel
cellular factor, probably a Tat- or TAR-associated protein.
While it is still too early in the investigative process to
proclaim with certainty the anti-viral properties of
camptothecins, the evidence clearly shows the potential of
drugs for that purpose.
6. OTHER USES
OF CAMPTOTHECINS
Plant Regulator
CPT is a selective plant growth regulator (Buta and
Worley 1976, Worley et a1. 1979, Buta and Spaulding 1986,
Tao and Buta 1986, Buta and Kalinski 1988, Kieber et a1.
1992). DNA topo I is the main target of CPT inhibiting plant
cells. CPT inhibited the seedling growth and seed germination
of some grasses and crops in which topo I is essential and
active. However, it was reported that CPT stimulated some
other species such as watermelon (Citrullus vulgaris Schrad.)
(Buta and Spaulding 1986). Therefore, managers can
effectively control the growth of some competing crops and
grasses with CPT in order to meet management goals.
Generally, CPT inhibits the growth of the taproot and
primary leaf of monocot seedlings more than those of dicots.
In some grasses and crops such as Italian ryegrasses (Lolium
multiflorum Lam.), barley (Hordeum vulgare L.), maize (Zea
mays L.), sorghum (Sorghum bieolor Moench.), wheat
(Triticum aestivum L.), and tall fescue (Festuca arundinacea
Schreb.), growth of seedlings is inhibited by CPT even at low
concentrations (50 11M). But in other grasses such as
Kentucky bluegrass (Poa pratensis L.) and ryegrass (Lolium
perenne L.), seedling growth is less affected. Growth and
germination of legumes (Fabaceae) is affected by CPT,
however, soybeans (Glycine max Merr.) and cowpea (Vigna
radiata L.) are less affected than other legumes such as red
clover (Trifolium pratense L.) and bird's foot trefoil (Lotus
corniculatus L.). In tobacco (Nicotiana tabaeum L.), seedling
growth is only affected at the high CPT concentration (500
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IlM). However, lettuces (Lactuca spp.) are inhibited by both
low and high CPT concentrations (50 and 500 IlM). Tomato
(Lycopersicon escuZentum Mil!.), broccoli (Brassica oleracea
var. itaZica), and mustard (Brassica campestris L.) are affected
by CPT. Interestingly, both seed germination and seedling
growth of watennelon is stimulated by CPT at both low and
high concentrations (Buta and Spaulding 1986).
Insect Chemosterilant
CPT alkaloid is also a potent chemosterilant against the
house fly (Musca domestica L., Muscidae, Diptera) (DeMilo
and Borkovec 1974). Fecundity and hatchability of the fly are
remarkably reduced after exposure. In China, the alkaloid is
also used for control of Masson pine caterpillar (Dendrolimus
punctatus Walker, Lasiocampidae, Lepidoptera), the most
serious forest pest in China (Hunan Institute of Forestry
1978). The mortality of larvae, pupae, and adults of insect
increased after treatment with CPT, and the hatchability of
eggs decreased after treatment with 0.05% CPT.
In addition, according to the Lanzhou General Hospital of
the Chinese People's Liberation Army (Chiao and Li 1974),
Psoriasis vulgaris was treated in 33 patients with the CPT with
improvement in all cases. CPT-dimethyl sulfoxide solution
was applied to psoriatic lesions 2-3 times daily. Twenty-one
patients were cured and the rest were greatly improved. No
constitutional reactions to the treatment were noted.
Ethnic Uses
The tree has been planted as a "four-sites" (waterside,
hillside, roadside, and homeside) tree throughout the
provinces south of Changjiang (Yangtze) River in China. Xi
Shu is also a nectariferous plant. However, to date there is no
report available about honey production from Xi Shu.
Other Uses 37
FIGURE 5. Specimen McClure 6546 (deposited at the Harvard
University Herbaria) collected on July 22, 1921 from Koung Tse
Paai (in Guangdong Province) indicates Xi Shu as "drug plant" in
the label (photos by D. E. Boufford, Harvard University).
It is commonly recognized that there were no medicinal
uses of the tree until its anti-neoplastic activity was discovered
in the 1960s. Also, it was not mentioned in Chinese herbal
books. But the label of the specimen F. A. McClure 6546
(deposited at the Harvard University Herbaria) collected from
Guangdong on July 22, 1921 indicates "drug plant", but
provides no further information on this use (Figure 5). In
fact, 35 ethnic groups are in the natural range of Xi Shu and
at least 16 local names of Xi Shu occur in China (see chapter
8). This variety of names may indicate the tree has important
human uses. Most probably, therefore, Xi Shu may be used
for medicine by native ethnics, but the uses are unknown to
others because of cultural and geographic barriers. An
ethnobotanical investigation is needed in future studies.

POTENTIAL
DEVELOPMENT
OF XI SHU
IN THE UNITED STATES
JJf pou plan for one pear, grow rice;
3f( POll plan for ten peartt, plant treett;
]( pou plan for a bunbreb peartt, ebucate people.
-Zuang Zi (c. 4th-3rd century B.C.)

7. SOURCES
OF CAMPTOTHECINS
Drugs Extracted from All Parts of Xi Shu
Unlike taxal found only in the bark of the Pacific yew,
camptothecins are present in all parts of the Xi Shu at all
stages of growth during all seasons of the year. J. S. Hsu and
co-workers (1977) found that the content of CPT occurs in
different parts of Xi Shu at the rate of 5:10:5:2:15 of roots: root
bark: stem bark: twigs: fruits (Table 3). According to Hsu and
associates, fruits have the highest content of all plant parts.
However, surprisingly, H. J. Tien and co-workers (1977)
reported that the leaves have higher content of CPT than
either fruits or roots (Table 3). G. R. Cao and others (1992)
reported that leaves contain 0.016% of CPT by dry weight.
Although the CPT content in leaves varied from report to
report, it has been observed that leaves contain sufficient
levels of CPT to cause death in goats feeding on the leaves
(Cao et a1. 1992). The common parts used for drug production
are bark or wood, but both fruits and leaves are still used in
China to treat leukemia and skin diseases, respectively.
In addition, K. Sakato and co-workers obtained CPT from
leaf callus tissues by using plant cell culture techniques
(Sakato and Misawa 1974, Sakata et a1. 1974).
The yield of HePT, another active compound, is low, and
amounts to only 0.002% of bark weight. K. P. Chu and co-
workers (1979) obtained HCPT from CPT with 10% yield by
biotransformation with fungi. This bio-connection provides
another opportunity for significant study in recovery of CPT
from Xi Shu.
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TABLE 3. Contents of camptothecin in various parts of Xi Shu.
Fruits Twigs Stem Bark Leaves Roots Root Bark
0.010% 0.016%.... 0.010% 0.020%O.030o/n 0.004%
0.030% 0.016%" 0.040%" 0.036%"
Notes: Dry weight basis. * From Tien el al. (1977); ** from Cao et a!. (1992);
others from Hsu et al. (1977).
Other Botanical Sources of .Camptothedns
The potent anti-tumor activity of CPT and its analogs and
the supply shortage of suitable trees stimulated scientists to
look other plants as sources of these compounds. T. R.
Govindachari and N. Viswanath (1972) isolated CPT, 9-
methoxycamptothecin (9-MCPT), and another related alkaloid
mappicine from Nothapodytes foetida (Wight) Sleumer
(formerly Mappia foetida Miers). N. foetida is a small tree of
Icacinaceae, it is distributed in southern India, Sri Lanka,
Burma, Thailand, Cambodia, Sumatra (Indonesia), Luzon
(Philippines), and Taiwan (China) (Chuang 1981). The genus
Nothapodytes Bl. contains 9 species and is restricted to
southeastern Asia. Six species are distributed in southern
China (Ku and Tang 1980). According to Govindachari and
Viswanath (1972) and Govindachari and others (1974),
contents of CPT and 9-MCPT in N. foetida is much higher than
those in Xi Shu (Table 4). J. S. Agarwal and R. P. Rastogi
(1973) and G. Raja and M. R. Heble (1994) support this result;
they also isolated 21-methylenecycloartanol from N. foetida.
S. Tafur and co-workers (1976) isolated CPT and 9-MCPT
from Ophiorrhiza mungos L., a herbaceous plant of the
Rubiaceae from Sri Lanka, India, Malaysia, Sumatra, Java,
and Guangxi and Yunnan of China. Ophiorrhiza L. contains
about 50 species and is restricted to tropical Asia. About 20
species have been identified in China (Ku and Tang 1980).
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TABLE 4. Contents of camptothecins in various parts of
Nothapodytes foetida.
Sources Stem Stem Bark Leaves Roots
Camptothecin 0.06% 0.08% 0.01% 0.10%
9-Methoxycamptothecin 0.001% 0.001% 0.002%
Notes: Dry weight basis. Data from Govindachari and Viswanath (1972) and
Govindachari et a1. (1974).
S. P. Gunsekera and others (1979) found that Ervatamia
heyneana (Wall) Cooke (also known as Tabernaemontana
heyneana Wall) contain low concentrations of CPT (0.00013%)
and 9-MCPT (0.00004%). E. heyneana is a shrub or small tree
species of Apocynaceae from southwestern India. The genus
Ervatamia Stapf contains 120 species in tropical Asia (Ku and
Tang 1980). Fifteen species are found in southern
ChinaCTsiang and Li 1977).
In summary, plants containing camptothecins are
distributed throughout Southeast Asia. All other species
except Xi Shu are tropical species. Ophiorrhiza mungos and
Ervatamia heyneana have very low contents of camptothecins.
N. foetida has a higher content of CPT than all other species.
But it is a small tree and restricted to a tropical climate.
However, Xi Shu is a fast-growing large tree and is easy to
grow in most warm and humid regions of the world.
Therefore, Xi Shu is the most promising species for
development of the camptothecin family of drugs.
8. BOTANY OF XI SHU
Phylogenetic Relationships
Xi Shu (Camptotheca acuminata Decaisne) is a Tertiary
relict and the only living species of the genus Campto theca
Decaisne. The genus had more members and wider
distribution in the Tertiary (Suzuki 1976, Tanai 1977). Like
many other monotypic taxa, the genus displays distinctive
morphology due to a long time independent evolution and is
relatively isolated in phylogeny. The genus Camptotheca is
now recognized in the family Nyssaceae by most taxonomists.
Nyssaceae is distributed disjunctly between Asia and
North America (Ying et a1. 1993). It contains three genera
Davidia Baillon and Nyssa Gronov ex L. and 11 species
besides Camptotheca Decaisne. Davidia is a monotypic genus
endemic to the southern China; its species Davidia
involucrata Baillon (dovetree) is only remotely related to
Camptotheca so that the genus is often treated as a separate
family.
Nyssa has 10 species and is distributed disjunctly between
eastern and southeastern Asia and eastern North America.
Nyssa aquatica L. (water tupelo), N. ogeche Bertr. ex Marsh.
(Ogeechee tupelo), and N. sylvatica Marsh. (black tupelo) are
distributed in eastern North America; N. javanica (Bl.)
Wanger. (Javan tupelo), N. leptophylla Fang et Chen (small-
leaf tupelo), N. shangszeensis Fang et Soong (Shangsze
tupelo), N. shweZiensis Airy-Shaw (Shweli tupelo), N. sinensis
Olivo (Chinese tupelo), and N. wenshanensis Fang et Soong
(Wenshan tupelo) are Asian species. Nyssa is relatively
related to Camptotheca, in particular, N. javanica and N.
sinensis might share a common ancestor with Camptotheca
acuminata. American N. aquatica is closely related to Asian
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N. javanica in fruit morphology (Titman 1949). Some of these
species were screened for anti-tumor activity in the Cancer
Chemotherapy National Service Center Screening
Laboratories during the middle 1960s. According to Perdue
and co-workers (1970), no antitumor activity of consequence
was demonstrated by any extract of Davidia involucrata,
Nyssa aquatica, N. biflora, N. javanica, or N. ogeche, and only
Nyssa sylvatica showed minimal activity.
Morphology and Taxonomy
Xi Shu (Camptotheca acuminata Decaisne) is the only
species of the genus Camptotheca Decaisne. It is native to
southern China. The tree was first recorded in the Zhiwu
Mingshi Tukao in 1848 (Wu 1848, see Figure 2). Based on
specimens collected by Father Armand David in Lushan,
Jiangxi Province during his 1868-1870 exploration in China,
Joseph Decaisne, Director of the Jardin Des Plantes, Paris,
scientifically described and named it in 1873. The genus name
Camptotheca is from the Greek-eampto (bend or curved) and
theca (a case), refering to the anthers which are bent inward
in a distinctive manner. The species name acuminata refers to
acuminate tips of leaves. In China, this tree is widely called
Xi Shu (:§:trll), which means happytree (or tree of joy). It is
also known as Han Lian (If!BD or Han Lian Mu (1'J!ii*) (dry
lotus tree, in Jiangsu, Jiangxi, and Sichuan), Huagan Zi Shu
(mff-=rW, in Yunnan), Qian Zhang Shu C'fiBHM, thousand·
sheet tree, in Sichuan), Qian Zhang Shu c::r3tW", thousand
zhang tree, in Sichuan), Shui Donggua (*~JJl, water white
gourd, in Sichuan), Shui Li Zi (*~T, water chestnut, in
Sichuan), Shuime Zi (*~f.mf, in Yunnan), Shui Tong Shu
(*~~, water tung tree, in Guangdong and Guangxi), Shui
Zong Shu (*~~, water palm, in Guangdong), Tian Zi Shu,
(~:f=$W, heavenwood tree, in Hunan), Tu Bajiao (±;\fi.!, wild
anise, in Guizhou), Yangqing Shu (~WfM, in Sichuan), Ye
Bajiao (!¥fI3"i{, wild banana, in Guizhou), and Yuan Mu ([jU*,
round wood, in Guizhou).
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Camptotheca acuminata Decaisne in Bull. Soc. Bot. France XX:157 (1873);
Baillon in Hist. PI. VI. 282 (1877); Franchet in Nouv. Arch. Mus. Paris II.
8:241, t. 9 (PI. David. 2:59, t. 9) (1886); Hemsley in Jour. Linn. Soc. XXIII.
346 (1888); Diels in Bot. Johrb. XXIX. 504 (1900); Dode in Bull. Soc. Bot.
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Camptotheca acuminata is a polygamo-monoecious
deciduous tree. It ean reach 30 m in height and 100 em in stem
diameter under favorable conditions. The trunk is usually
without branches for 10 m above the ground (Figure 6). Its
lightly gray rough bark is cracked and fissured (Figure 7).
Twigs are gray-green, and young ones are red or green and
usually pubescent (Figure 8). Leaves are simple,
alternative, papery, pinnately veined, ovaloblong to oblong-
elliptic, slightly pubescent, acuminate, entire, occasionally
toothed, 10-30 cm long and 6-15 em wide, lateral veins 11-15
on each side, with 1.5-3.0 em long stalk. Usually, two sessile
flowers form a cyme, and 15-30 cymes form a dense global
head (1.5-2.0 cm in diameter). Two to ten heads are arranged
into a terminal or axillary raceme-like or panicle-like
compound inflorescences (Figure 9). Flowers in heads on the
upper part of the compound inflorescence are bisexual and
bloom first, and those on the lower part are male or
sometimes bisexual. Bracts are three, triangular ovate,
pubescent. Calyx are cup-form, 5 toothed, margins ciliate.
Petals are 5 valvate, 2 mm long, light green, and pubescent.
Ten white stamens grow in two whorls, and the outer matures
first (Figure 10). Filaments are slender, glabrous; anthers
are apicifixed and 4-locular. Pollen is 3-colporate, suboblate,
obtuse-triangular in polar view, 29-38 J.lffi (polar axis) x 38-54
IJ.m (equatorial axis), sexine punctitegillate. Colpi is not very
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FIGURE 6. A 12-year old Xl Shu in Kingwood, Texas is 13 m in
height and 18 em In diameter measured 811.4 m in height in June
1993 (photo by L. R. Lowrey, Anderson Landscape and Nursery).
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FIGURE 7. The bark of XI Shu is slightly gray and fissured (pholo
by P. R. Blackwell, Tucker Center).
FIGURE 8. Young twigs of XI Shu are dark red or greenj the older
ones are gray·green (photos by T. R. Moore. XyloMed Research
Foundalion).
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FIGURE 9. Xi Shu has showy white nowers in May·August. 30-60
Dowers Corm the head and 2· to heads are arranged into a terminal
or axillary raceme-like or panicle. like compound innorcsccnce
(photo by Z. L. Nang. Jiangxi Agricultural University).
distinct, and colpi margins are provided with nexinous
thickenings (Erdtman 1966). At pollen shedding, each
sporangium dehisces inwards without forming two cavities.
The suture of the anthers is spiral. A ring-like nectar exists
between the stamens and pistil. The pistil consists of three
(two) carpels, with one glabrous two- or three-lobed style.
Ovary is interior, unilocular, and has one ovule per locule.
Flowers bloom in May-August. Fruits are sama.fa-Iike,
sessile, disc persistent, grouped in globose heads (apitula).
2.5-3.0 em long and 6-9 mm wide, glossy brown, with 3-8 em
long stalk (Figure 11). The fruits ripen in September-
November. Usually, trees start to bear fruits at ages of 7-10.
Cotyledons (Figure 12) are simple, glabrous, laneeolate,
t"". ":'-0:;-:"' r ,
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FIGURE 10. Camptotheca acuminata Decaisne (modified from
Flora Sichuanica, 1981. A-male flower; B-male flower without
petals; C-female flower without petals; D-fruit inflorescence; E-
fruit; F-floral shoot).
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FIGURE 11. Fruits of Xi Shu are samara-like. sessile, 2.5-3.0 em
long (photo by P. R. Blackwell. Tucker Center).
FIGURE 12. Cotyledons are simple, glabrous, opposite, lanceoJate.
sessile (photo by L. R. Lowrey, Anderson Landscape and Nursery).
52 XI SHU
2-4 em long, about 1 cm wide and the two are opposite.
Chromosome number (2n) is 44.
The wood is light yellowish brown, occasionally with
dark-tinged sapwood, without special odor. The wood is
moderately soft and light with a rather curly grain, which has
a fine to very fine texture. Annual rings are moderately
distinct and inner ones are wider. The wood has fine rays and
small, numerous, evenly distributed pores. It will not take a
smooth cut, but can be split off along the rings. It is easy to
dry under natural conditions, but tangential fissures and
radial cracks develop when the wood is air dried. The wood is
not rot-resistant. Root rot is a major disease. The wood may
be used for packaging materials and paper-making.
Industrial oil can be extracted from the fruit.
There are two varieties of Camptotheca acuminata except
for the original variety var. acuminata.
1. Camptotheca acuminata var. tenuifolia Fang ct Soong in Act.
Phytotax. Sin. 13(2):86. pI. 14, f. 3, 1975; Fang and Zhang in Fl.
Reip. Pop. Sin. 52(2):144-146, 1983.
The Chinese name ofvar. tenuifolia is Baoye Xi Shu
(~~*W, tenuous leaf happytree). The variety is identified
based on the specimen collected from Huaiji County,
Guangdong Province. It is distinguished by its longer fruit
(3.0-3.2 cm long) and smaller leaves (8-10 em long, 4-6 em
wide with 11-12 lateral veins on each side) (Figure 13). The
type (Bingming Zhang 20309, November 4, 1952) is deposited
at the Herbarium of Sichuan University at Chengdu, Sichuan
Province. The tree grows to 5 m in height and is found
growing along streams at Luegang Xiang, Huaiji County.
2. Camptotheca acuminata Decaisne var. rotundifolia Yang et Duan
in Nat. Sci. J. Hunan Norm. Univ. 11(1):63-64 (1988).
The Chinese name ofvar. rotundifolia is Yuanye Xi Shu
(1Il~¥:filJ, round leaf happytree). It was recently found
growing in Nanxian County, Hunan Province, China. It differs
from var. acuminata and var. tenuifolia by brown bark, a
round or sub-round and small leaf (4.5-6.5 em long, 5.5-6.5
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FIGURE 13. Camptotheca acuminata Decaisne var. tenuifolia
Fang et Soong (after Fang and Soong 1975, type specimen;
Bingming Zhang 20309).
em wide, with 4-7 lateral veins on each side) (Figure 14). The
type (Lindong Duan 1001, August 1981, at 45 m above sea
level) is deposited at the Herbarium of Hunan Normal
University at Changsha, Hunan Province. The tree grows to
10 m tall and is found at low elevations.
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FIGURE 14. Camptotheca acuminata Decaisne var. Totundifolia
Yang et Duan (after Yang and Duan 1988).
9. GEOGRAPHY OF XI SHU
Natural Range
Xi Shu is a Tertiary relict. It was widely distributed in
Japan in the Tertiary Period (Suzuki 1976, Tanai 1977). It is
now native only to central, southern, and southeastern China,
including Anhui, Zhejiang, southern Jiangsu, Jiangxi, Fujian,
Hubei, Hunan, Guangdong, Guangxi, Guizhou, Sichuan, and
Yunnan provinces (Figure 15). Xi Shu usually grows in
moist and fertile sites below 1,500 m in elevation, especially in
thickets, but is occasionally found up to 2,400 m in elevation
in the southern portion of its range. It occurs on deep, well-
drained, friable clay soils at the edges of forests, on slopes,
and along streams.
Cultural Range
In China, Xi Shu is widely cultivated as an ornamental
"four-sites" tree within its natural range and Henan and
Taiwan provinces. It is also largely planted beside irrigation
ditches as a firewood species because of its rapid growth and
regeneration. The species was introduced into Japan, South
Korea, Europe, and the United States in this century.
United States
The first introduction of Xi Shu to the United States was in
1911 (Perdue et a1. 1970) (Figure 16). The seeds collected
from the Ornei Mountain, Sichuan Province by E. H. Wilson
(No. 4405) were sown at the Arnold Arboretum (USDA 1915).
No records are now available indicating further distribution
by either the Arnold Arboretum or the USDA (Perdue et a1.
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FIGURE 15. Natural distribution of Xi Shu in China (the dots-
Camptotheca acuminata var. acuminata; the star-Co acuminata var.
tenuifolia Fang et Soong; and the square-Co acuminata var.
rotundifolia Yang et Duan).
1970). According to computer searches and personal
interviews with P. White and S. Kelley at the Arnold
Arboretum (1994), there is no living collection and even no
record of it ever having been at the Arnold Arboretum.
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FIGURE 16. Early introduction of Xi Shu in the United States.
In 1927, seeds collected from Jiangsu Province, China by
W. T. Swingle (No. 803) were sown in Los Angeles, California
(Perdue et a1. 1970). However, no records are available on
survival and redistribution of the seedlings (USDA 1929).
In 1934, seeds Steward No.75 were received by the USDA
in April 1934 and accessioned in April 1939 as P.I. 132293. The
seeds were sown at the Plant Introduction Station at Glenn
Dale, Maryland in June 1934 (USDA 1950). About 150 plants
were available in 1935. Some of these plants were distributed
in Honolulu, Hawaii; San Diego, California; Mayaguez, Puerto
Rico; and Atkins Garden near Cienfuegos, Cuba in 1937; and
Chico, California in 1938 (Perdue et aI. 1970). Only two trees
at Chico have survived (Perdue 1968, see Figure 17). The
Steward No. 75 was collected by A. N. Steward, a professor at
the College of Agriculture and Forestry at Nanjing University
(now the Nanjing Forestry University) from Changan, Yung
Hsien, but the record did not indicate which province. There
are at least two counties named after Yung Hisen (or Jung
Hsien, Yung Xian) in China. One is in northern Guangxi
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FIGURE 17. A 60 year-old mature tree of Xi Shu in Chico,
California, August 1994 (photo by L. E. Hartman. USDA Forest
Service).
Province, 50 miles north of Liuzhou. Another one is in
southwestern Sichuan Province, 38 miles east of Loshan. The
seeds may have been collected from one of these two counties.
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In 1935, the Arnold Arboretum received seeds from
Lushan Arboretum and Botanical Garden, Jiangxi Province.
The seeds were sown in pots in February 1935 and died in
1942. This introduction was not distributed (Perdue et a1.
1970).
In 1949, Willard Hagen in Arcadia, California obtained
seeds from Lushan Arboretum and Botanical Garden. The
plants raised from these seeds were distributed to private
purchasers, city parks, and botanical gardens on the west
coast from California to Washington; but less than 30 trees
were found in the United States before 1965. During the late
summer of 1965, most of the trees were harvested for drug
collection with probably only TWO trees left at the Chico
Plant Introduction Station (seed source: Steward No. 75, from
Jiangsu) and 0 NE in Los Angeles State and County
Arboretum (1952 from Hagen Nursery, which had received its
seed from Lushan, Jiangxi). After discovery of the tree's anti-
tumor activity, Xi Shu reproduction increased rapidly. Chico
Plant Introduction Station (now Genetic Resource Center) in
California started to produce seedlings from its two trees in
1964, reaching 1,300 seedlings in 1966, 5,000 by 1967, and
8,500 in 1992. Current collections in many gardens and
nurseries in the United States are from this seed source (or
originally Steward No. 75 from Jiangsu).
In 1966, the New Crops Research Branch (NCRB), Crops
Research Division, Agricultural Research Service, USDA
received seeds from Taiwan (as I.P. 317685-317688, see USDA
1969). The seeds were collected from four trees by Ta-Wei He
at the Forestry Division of the Joint Commission on Rural
Reconstruction, Taipei. No record indicates the distribution of
the seeds.
In 1971, the NCRB of USDA obtained seeds from Japan
(USDA 1974). The seeds were collected by R. E. Perdue from
a single tree at the Kyoto Botanical Garden, Kyoto (Perdue
No. 10265) and two trees at the Kamigamo Experimental
Forest of Kyoto University (Perdue No. 10267). The tree at
Kyoto Botanical Garden was about 25 years old then and the
two trees from Kamigamo were originally from it. The seeds
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probably were sown at the Plant Industry Station, Beltsville,
Maryland. No record indicates further distributions from this
collection.
The Genetic Resource Center, USDA at Chico has
received seeds from many sources since 1991. The main seed
sources include (L, E. Hartman, peTS. comm., September
1994):
• China: Tongshan, northern Anhui; Zhoushan, Zhejiang;
Nanjing, Jiangsu; Changsha, Hunan; Wuhan, Hubei;
Luzhou, Sichuan; Shanghai; and Guangxi
• Japan: Kyoto University Experimental Forest Station
• United States: Smith College, Massachusetts (from
Korea, unknown origin), Texas A & M University,
Texas (from China, unknown origin), Yucca Do
Nursery, Texas (from Chico?), and Anderson Landscape
and Nursery, Houston, Texas (from San Antonio,
originally from Chico?),
Seedlings grown from all of the above listed seed have
been planted in a 2.5 acre breeding arboretum at Chico for
long term seed and cutting production (Figure 18).
Nurseries in Montana, Hawaii and California, recently
purchased seeds from China. The seeds are distributed to
several nurseries in the United States.
At present, Xi Shu has been introduced into California
and most states of the southeastern United States. The Chico
Genetic Resource Center has established a 1.5 acre plantation
planned for harvest in 1995 under an agreement with the NCr
(L. E. Hartman, pers. camm., September 1994). However, the
seedlings or young trees are largely grown in gardens and
experimental field plots, and Xi Shu plantations are still in an
early trial stage especially in the southeastern United States.
The genetic quality of the tree is a critical problem in the
development of plantations because the seed source is limited.
In South Carolina, E. Cuthbert received seeds from Hurov
Tropical Seeds, Honolulu, Hawaii in 1970. One tree in
Summerville, South Carolina is now about 11.5 m tall and 16
em in diameter. The tree has never shown any obvious
Geography 61
FIGURE 18. Xi Shu seed orchard of the USDA Forest Service at
Chico, California, August 1994 (photo by L. E. Hartman, USDA
Forest Service).
damage from drought and hurricane Hugo (the eye of the
storm passed directly over the tree, Cuthbert, pers. camm.,
August 1994). The growth of the tree is slow largely because
it is shaded by several larger trees around it.
In Texas and Louisiana, plantation trials of Xi Shu started
in the early 1990s. The seeds or seedlings are basically from
L. R. Lowrey at Anderson Landscape and Nursery, Houston,
Texas. In 1979, Lowrey received about 20 seedlings from the
San Antonio Botanical Center, Texas. The San Antonio
parent tree was about 10 years old then, it is probably from
one of the two mother trees at Chico, California. Lowrey and
K. K. Ferguson distributed these seedlings in Texas in the
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early 1980s, and two trees are left today: one in Kingwood (in
D. Morgridge's back yard) and the other in Houston (at the
Stehlin Foundation for Cancer Research). These trees started
to bear fruit in the late 1980s. The seeds or seedlings from the
Kingwood tree were distributed to many of above people or
organizations in Texas and Louisiana by Lowrey and T. R.
Moore of the XyloMed Research Foundation at Monroe,
Louisiana (see Louisiana Public Broadcasting Report on Tracy
and Camptothecins, video type produced by Arcie Chapa
Broadcast June 3, 1993 and Tracy and the Tree of Joy, video
tape produced by JRWL Videomaker LLC 1994).
The San Antonio parent tree was destroyed several years
ago. Fortunately, one tree from this parent tree is growing at
the San Antonio Zoo, Texas. The seedlings reproduced from
seeds of this tree were sent to the National Arboretum in
Washington D.C. in 1991.
In 1991, Lowrey obtained two pounds of seeds from a seed
company in Montana. The seeds were collected from Zhejiang
Province, China. In 1993, Lowrey received seeds from
Cuthbert who collected seeds from his Summerville tree.
Seedlings were raised from these seeds, and some plants were
propagated by cuttings from these seedlings and the
Kingwood tree, by Lowrey and his son-in-law and daughter,
M. and P. Anderson in Houston, Texas. Lowrey and his family
have donated seeds and seedlings directly to many people and
organizations throughout the United States since 1991. These
people and organizations include:
• D. L. Creech and S. Y. Li of Stephen F. Austin State
University, Nacogdoches, Texas (30 seedlings)
• M. Ellis of Gibbs Brothers in Huntsville, Texas (now
with Black Stone in Houston)
• L. Atlas in Houston, Texas (later, Atlas gave his
seedlings to TreeCo in Oregon specializing in tissue
culture and fruit tree understocks)
• San Antonio Botanical Center in Texas (50 seedlings)
• USDA Genetic Resource Center (formerly Plant
Introduction Station), Chico, California (50 seedlings)
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• Sam Houston State University, Huntsville, Texas
(hundreds of seedlings)
• J. Harrington of Orange, Texas
• Lowrey's sister and cousin at Sulphur, Louisiana
• M. Brennan of the Louisiana-Pacific Corporation, New
Waverly, Texas
• T. R. Moore in Monroe, Louisiana (about 600 seedlings).
Moore received the plants from Lowrey and his family in
the late fall 1992. He also received 5 pounds of seeds from a
seed company in Montana by the end of 1992. He gave the
seedlings and seeds from these sources to universities and
companies for field trials and laboratory tests:
• G. H. Weaver and J. Adams of the School of Forestry at
Louisiana Tech University, Ruston, Louisiana. The
seeds were sown in February 1993 and about 2,000
seedlings are growing well at the Columbia Nursery,
Columbia, Louisiana.
• S. Carpenter and Z. J. Liu of the Louisiana State
University School of Forestry, Wildlife, and Fisheries.
These seedlings were planted at LSD experimental
stations in New Iberia and Port Sulphur, Louisiana.
About 500 seedlings are growing very well in Port
Sulphur (Figure 19). In addition, they received about
200 seedlings from Weyerhaeuser Company in the
spring 1994; these seedlings came from seeds of the
Chico trees.
• Boise Cascade in DeRidder, Louisiana has a seed tree
farm with about 100 plants established. In the fall of
1993, Moore founded the non-profit XyloMed Research
Foundation in Monroe, Louisiana to support studies of
Xi Shu.
Studies on propagation by cuttings and field trials are now
being conducted by almost all of these institutions and
individuals.
In addition, field trials are being conducted in southern
Arkansas. In the fall of 1992, about 100 seedlings were
planted in Crossett, Arkansas by Georgia-Pacific Corporation.
The seedlings were from Louisiana Tech University. Field
64 XI SHU
FIGURE 19. A XI Shu planlation including 500 seedlings was
established by the Citrus Research Slation in Pori Sulphur,
Louisiana in early 1993 (photo by T. R. Moore. XyloMed Research
Foundation).
trials are also being conducted in Louisiana by International
Paper Company.
Other Countries
Xi Shu trees are available in many gardens and
experimental forests in Japan and South Korea. In the
United Kingdom, Xi Shu has been introduced several times.
According to R. J. Pankhurst (pers. comm., August 1994), for
example, the Royal Botanic Garden in Edinburg introduced Xi
Shu from China in 1980. The source is unknown and no
provenance information is available. In 1993, there were two
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direct seed introductions from China by the Royal Botanical
Garden. On April 14; seeds were received from Kunming
Botanical Garden, Yunnan, China, but the origin is wild and is
not known. Two months later, the garden received seeds from
the Shanghai Botanical Garden, Shanghai, and the wild origin
was from western Zhejiang (400 m at elevation, 30 0 30'N
119"17'E).
10. ECOLOGY OF XI SHU
Synecological Feature
Xi Shu is a shade-intolerant species (Figure 20). It is a
canopy species but less dominant in mixed evergreen and
deciduous hardwood forests, especially at elevations from
1,000 to 2,000 m in the central subtropical region of China
(Chou and Li 1990). The forest canopy is usually 15-20 m
high. According to Y. L. Chou and S. Y. Li (1990), the upper
canopy consists of Xi Shu and other deciduous species,
including Fagus longipetiolata Seem., F. Zucida Rehd. et Wils.,
F. engleriana Seem., Sapium japonicum Pax et Hoffm.,
Cyclocarya paliurus (Batal.) Iljinskaja, Alniphyllum fortunei
(Hemsl.) Perk., Meliosma spp., Liquidambar acalycina Chang,
Acer sinense Pax., Carpinus fargesiana Winkl., Toxicodendron
succedaneum (L.) Kuntze, and Nyssa sinensis Olivo The lower
canopy largely includes evergreen trees such as
Cyclobalanopsis glauca (Thunb.) Oerst., C. oxyodon (Miq.)
Oerst., Castanopsis eyrei (Champ. ex Benth) Tytch., Schima
supera Gardn. et Champ., and Lithocarpus spp. In addition to
Xi Shu, the forest contains some other Tertiary relics such as
Davidia involucrata Baill., Liriodendron chinense (Hemsl.)
Sarg., Cercidiphyllum japonicum var. sinense Rehd. et Wils.,
Tetracentron sinense Oliv., AescuLus chinensis Bunge, A.
wilsonii Rehd., Bretschneidera yunshanensis Hemal., Euptela
pleiospermum Hook. et Thomas., Dipteronia sinensis Oliv.,
and Eucommia ulmoides Olivo (Chou and Li 1990). The
undergrowth species are numerous. Sinarundinaria spp. and
ferns are relatively common. Xi Shu does not regenerate well
naturally in a closed forest, but the seedlings grow well in
open places (Figure 21).
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FIGURE 20. Xi Shu is a shade-intolerant species. A 2 year old
seedling under dogwood (Cornus florida) canopy is only 2S em tall,
while the seedlings or the same age under full sunlight can grow up
to 2 m tall (pholo by S. Y. Li, Tucker CCnlcr. July 15. 1994).
FIGURE 21. Xi Shu regenerates well naturally under the parent
tree, especially in shade gaps (photo by L. R. Lowrey. Anderson
Landscape and Nursery).
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FIGURE 22. Monthly changes in mean percentage of possible
sunshine in the natural range of Xi Shu in China and its potential
range in the southeastern United States (1961-1990).
Autecological Feature
The ecological requirements of Xi Shu are largely a warm
and humid subtropical climate and fertile well-drained
subtropical soils. The environment of its native range in
China is favorable for the growth of Xi Shu. The annual
mean percentage of possible sunshine ranges from 28 to 57
within the natural range of the tree (see Appendix Table 1).
Normally, sunshine is least in the spring (Figure 22). The
growing season is usually 250-300 days. The monthly mean
temperatures display a bell shaped curve over the year
(Figure 23). The annual average temperature varies from
15°C to 23.0°C at low elevations within the natural range (see
Appendix Table 2). At higher elevations (above 2,000 m), the
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FIGURE 23. Monthly changes of mean temperature in the natural
range of Xi Shu in China and potential range in the southeastern
United States (1961-1990).
annual average temperature may decrease to about 10cC.
The mean temperature of the coldest month (January) ranges
from 2"C to 14"C, and the recorded low temperature is -20cC
(Chou and Li 1990). Annual precipitation is usually 1,000-
2,000 mm and about 75% falls in the April-September
(Figure 24, see Appendix Table 3). However, winter drought
is evident throughout the range. Relative humidity is usually
about 80% especially during the growing season (Figure 25,
see Appendix Table 4). Xi Shu is more likely to be found
along moist valley bottoms than on the upper slopes. The
soils in the natural range are red and yellow podzolic soils
with a pH ranging from 4.5 to 6.0, but slightly acid soils favor
the growth of the plant (J. C. Ran, pers. comm., May 1994).
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range of Xi Shu in China and potential range in the southeastern
United States (1961-1990).
Ecological Conditions of the Potential Cultural
Range
The physical environment of the southeastern United
States, especially temperature and soil conditions, are similar
to those of the natural range of Xi Shu in China. Therefore,
Xi Shu may be fully adaptive to the southeastern United
States (roughly at the 1990 USDA Plant Hardiness Zone 8a,
8b, 9a, and 9b). In East Texas, for example, young plants
have grown rapidly and are root hardy after growing outdoors
for only a few weeks. But, there are several reports of frost
damage to Xi Shu in East Texas and San Antonio, Texas
(David L. Creech and Paul Cox, pers. comm., August 1994),
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range of Xi Shu in China and potential cultural range in the
southeastern United States (1961-1990).
The terminal buds of the plant are often damaged at low
temperatures of O°C. In Summerville, South Carolina,
however, a tree planted in 1970 has no obvious damage from
an overnight low temperature of -13°C (Edmund Cuthbert,
pers. comm., August 1994). In Chico California, trees have
escaped winter damage from the mean January temperature
of 7.3 D C and a low temperature of -11.7°C (Perdue et al. 1970).
Young plants survived for several years with minimum
protection at Glenn Dale, Maryland, where mean January
temperature is 1.3 D C (Perdue et a1. 1970). It was also reported
that Xi Shu has withstood temperatures of -12 D C without
damage in South Korea (Meyer 1991). Such differences in
cold tolerance may result from different seed sources
(probably different ecotypes).
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Xi Shi is a photophilous species. The tree is shade-
intolerant, but the seedlings may grow well under the tree.
The mean percentage of possible sunshine during June-
August reaches 60 to 70 in the southeastern United States (see
Figure 22) and 70 to 90 over most of the central and western
United States (Perdue et a1. 1970). The amounts are much
more than those of the natural range in China where the
percentage is usually less than 50 from June to August. This
extra sunshine in the United States should be favorable to the
growth of Xi Shu.
Xi Shu is not drought-tolerant, especially during the
growing season. In its natural range in China, rainfall is
greatest in the summer, and Xi Shu grows well under those
natural conditions. But in the southeastern United States,
rainfall is evenly distributed among all seasons (see Figure
24). Thus, Xi Shu may suffer from lack of adequate available
moisture during the growing season. For example, over half
of 1,000 seedlings planted in Plaquemines Parish, Louisiana,
were lost from dry weather in May 1994 (Tracy Moore, pers.
camm., August 1994). Therefore, an irrigation system should
be considered when plantations are established in the field
(Figure 26).
Pure Xi Shu plantations are easily managed and
harvested. However, ecologically, it may be better to
establish Xi Shu plantations mixed with other hardwoods. For
example, there are no large area, healthy, pure Xi Shu
plantations in southern China. Studies are needed to
determine species that should be associated with Xi Shu.
According to the native communities in China, species of
Nyssa, Acer, Carpinus, Aesculus, and Liriodendron appear to
be possible associates of Xi Shu.
__________ .. ., .. .. _~~?lo__'=gy"'___ _7_3
FIGURE 26. An irrigation system should be considered when
plantations are established in the field (photo by L. E. Hartman,
USDA Forest Service).
11. REPRODUCTION AND
GROWTH OF XI SHU
Pollination
Cross-pollination is the major breeding system of Xi Shu,
and neither self-fertilization nor agamospermy are observed
(Chen et a1. 1991). Smith (1969) found that no fruit develops
from the terminal flower when it is isolated from other
flowers in the same head. But fruit develops normally when
the complete head is enclosed in a paper bag. The stamens
are shed nearly one week before the stigma of the same
flower becomes receptive; this protandry leads to cross-
pollination (Chen et a1. 1991).
Pollination of Xi Shu is obligatory entomophilous, and
fruit production depends on the activities of pollinating insects
(Chen et a1. 1991). According to L. J. Chen and co-workers
(1991),24 species of visiting insects have been recorded. They
belong to Hymenoptera [bees and wasps, such as Apis cerana
Fabr, Ceratina hieroglyphica Sm., Hylaeus sp., Nom ia
chalybeata Sm., Pareumenes quadrisoinosus transitorus Liu,
Polistes formosanus Sonan, and Vespa tronica aucalis Smith].
Lepidoptera [butterflies. including Argynnis hyperbius (L.),
Graphium doson postianus (Fruhstorfer), G. sarpedon
connectens (Fruhstorfer), Papilio polytes pasikrates
Fruhstorfer, P. protenor amaura Jordan, Pieris canidia (L.), P.
almana (L.), Polygonia calbum asakurai Nakahara, Radena
similis (L.), and Tacoraea opalina hirayamai (Matsumura)},
Diptera [flies, including Chrysomyia defixa (Walker),
Sarcophagidae sp., and Syrphidae sp.], and Coleoptera
[beetles, such as Potosia serata (Erichson)]. Pollination
results in an average fruiting rate of over 60%. Petals of
flowers are small and green in color and thus are
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inconspicuous. However, stamens have yellow anthers which
are very attractive to many insects. Conspicuousness of the
stamens is enhanced by their radiate arrangement on a head
and by the mass flowering at the same time. Also, nectar and
abundant pollen are rewards to insects as full anthesis.
Production of seed is vigorous. In Chico, California, two
mature trees (about 30 years old then) produced enough seeds
to plant about 4 hectares (10 acres) per year at a rate of
17,780 seedlings per hectare (7,000 seedlings per acre)
(Perdue 1968).
Seed Gennination
Seed germination can be a problem in the reproduction of
Xi Shu by seeds. Seeds of Xi Shu usually do not germinate, or
have delayed germination at room temperature (Shao 1989,
Zhou 1989). Less than 5% of seeds germinated in 30 days at
stable temperatures (e.g., lS·C, 20·C, 2S·C, 30·C, and 35·C)
(Shao 1989). Studies suggest that inhibitory materials in the
seed coat are the main factors influencing this pattern of seed
germination (Shao 1989, Zhou 1989). Germination rates
exceeding 70% were obtained when the seed was either
removed from the fruit or left in fruit that had been dried
before planting (Smith 1969).
Germination may be increased either by stratification or
by moderate drying with artificial heat. Following
stratification at 0-5°C alone for 30 days, the germination rate
rose to 83.5% in only 8 days (Shao 1989). The germination
rate was 73.5% at temperatures of 20/30·C without
stratification. The most satisfactory treatment will probably
be a combination of heating and stratification (Perdue 1968,
Perdue et a1. 1970). The highest germination rates were
achieved when seeds were illuminated at a light intensity of
1,000 lumens for 8 hours per day, or subjected to temperature
regimes of 30'C during the day and 20°C at night, then
stratified at S·C for 40 days (Zhou 1989).
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Presently, reproduction by seeds is a major method of
seedling supply in the United States (Figure 27 and Figure
28).
Vegetative Propagation
Xi Shu has great coppice ability and can be propagated
vegetatively (Figure 29 and 30). In preliminary studies in
Chico, propagation by both cutting and budding proved
successful (Smith 1969). With "T" budding, the best results
were obtained in September when the scion-wood was more
mature. Leafy cuttings taken in early summer gave the most
satisfactory rooting and produced healthy, vigorous stock.
Trials by the authors at Stephen F. Austin State
University show that successful shoot cuttings can be taken
from late March to June. Lowrey's experiment at the
Anderson Landscape and Nursery, Houston, Texas shows a
similar result (L.R. Lowrey, pers. comm., August 1994).
Propagating material should be cut from healthy dormant or
new shoots. Straight cuttings range from 5 to 20 em long and
0.5-1.5 em in diameter. At least two nodes need to be included
in each cutting with the basal cut just below a node and the
top cut 1-2 em above a node. Cuttings root well under natural
conditions although they may show better results when
treated prior to planting with root-promoting substances such
as indolebutyric acid (lBA). Cuttings may be planted
immediately or kept for several weeks packed in peat moss
before planting.
Growth
Xi Shu grows rapidly, especially in the first 10 years in
favorable conditions. Two and one-half year old seedlings at
Sulphur, and Port Sulphur, Louisiana reached 4 m in height
(Figure 31). OUf observations show that the growth of
seedlings produced either by seeds or cuttings under a closed
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FIGURE 27. Seedlings grown from seeds by Anderson Landscape
and Nursuy, Houston, Texas, April 1992 (photo by L. R. Lowrey,
Anderson Landscape and Nursery),
FlGURE 28. 90-em taU seedlings in the Columbia Nursery,
Columbia, Louisiana on August 29 1994. The seeds, from Montana
and South Carolina, were sown In the spring of 1994 (photo by S.
Y. Li. Tucker Cenler).
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FIGURE 29. First year coppice regrowth (rom 8 2 year-old
seedling cut near ground level in October 1993, SFASU
Arboretum. Nacogdoches, Texas (photo by S. Y. Li. Tucker Center).
FIGURE 3D. Coppice sprouts, XI Shu, Port Sulphur, Louisiana
(photo by S. Y. Li, Tucker Center).
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FIGURE 31. A two and one-hair year-old seedling measuring 4 m
in height in Port Sulphur, Louisiana on Augusl 27. 1994 (photo by
T. R. Moore. XyloMed Research Foundation),
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canopy started about one month later than those in less
shade. The seedlings under full shade usually did not survive
while those under full sun grew very fast and averaged about
three times taller than those under partial shade. Annual
height growth under full sun can average more than one
meter in the first 10 years (Saito and Shidei 1968). Mature
trees can reach 30 m in height and 100 em in diameter under
favorable conditions.
According to Saito and Shidei's observation in Kyoto, the
individual leaf longevity is rather short: 70% of the total
leaves in a year will emerge in spring. These leaves are small
and usually last only one or two months. None of the leaves
that emerged in spring or summer lasted to the end of fall. In
East Texas, however, leaves that emerged in the spring were
large and lasted the entire growing season. Further studies of
the lack of leaf longevity of Xi Shu seem necessary if leaves
are to be source of camptothecins.
Maximum leaf biomass was 0.45 kg/m2 (dry) in July, and
maximum gross biomass of the plant (leaf, stem, and root)
reached 1. 7 kg/m2 (dry) in September (Kawahara et a1. 1968).
According to Kawahara and co-workers (1968), nutrient-
uptake by trees was relatively large in the early growth
period, especially in July, and 50-70% of total nutrient-uptake
returned to the soil via leaf-fall by the end of the year. The
total dry matter nutrient content was measured in September
as: potassium, 19.2 g/m2; nitrogen, 16.8 g/m2 ; calcium, 10.3
g/m2 ; magnesium, 8.6 g/m2; and phosphorus, 12.8 g/m2 • The
amount of inorganic nitrogen and available phosphorous in
the soils are important to the growth of Xi Shu. Thus,
silvicultural practices are needed in the plantation (Figure
32).
Biomass of each part, except branches, appeared to be
little affected by differences in stand density (Saito 1980).
Therefore, seedlings can be planted at higher densities (2,000-
7,000 trees/acre) if plantations are managed for drug
production.
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FIGURE 32. Laying mulch under Xi Shu in the seed orchard,
USDA Forest Service, Chico, California (photo by L. E. Hartman,
USDA Forest Service).
12. PROTECTION OF XI SHU
Diseases
Leaf spot is one of the most common diseases of Xi Shu in
China. The primary pathogens for leaf spots are Cercospora
camptothecae Tai (Dothideaceae, Dothideales, largely in
Jiangxi), and Pseudocercospora camptothecae Liu et Guo
(Dothideaceae, Dothideales, in Zhejiang, Hubei, Hunan,
Guangdong, Sichuan, and Yunnan), Alternaria spp.
(Pleosporaceae, Dothideales, in Hubei and Hunan),
Phyllosticta spp. (Phacidaceae, Phacidiales, in Rubei, Hunan,
and Jiangxi), Macrophoma spp. (Sphaerioidaceae,
Sphaeropsidales, in Jiangxi). Cercospora camptothecae Tai has
been recorded in Florida along with Puc c i n iasp.
(Basidiomycotina, Uredinales), another fungus host on Xi Shu
(Affieri et a1. 1984, Farr et a1. 1989).
The infected leaves by Cercospora camptothecae Tai (Tai
1948) and Pseudocercospora camptothecae Liu et Guo (Liu and
Guo 1987, Figure 33) show brown or black leaf spots. Spots
are irregular, many are gray, yellowish brown, or brown with
dark dots in the centel' that denote the mass frucitification of
the fungus. They are usually 1-8 mm in diameter. As the
disease progresses, the spots enlarge until the entire leaf is
affected. The disease reduces the yield and lowers the quality
of fruits. Also, fallen leaves from infected plants provide
organic matter as a food source for other fungi. This often
increases the severity of stern and root rot infections.
About 400 species of Cercospora and Pseudocospora have
been found on a wide variety of crops and trees, particularly
in warm, humid regions. Conidia of these fungi vary greatly in
size. For example, Cercospora camptothecae measures 37.0-
60.0 x 3.6-4.3 J..Lm, while Pseudocercospora camptothecae Liu et
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FIGURE 33. Pseudocercospora camptothecae Liu et Guo (specimen
HMAS 50504, after Liu and Guo 1987. l-conidiophores; 2-conidia;
3-stroma; 4-superficial hyphae).
Guo is from 6.0-104.0 x 2.5-4.0 Ilm (Liu and Guo 1987). The
slender, colorless conidia are straight to curved and have
several crosswalls. The conidia are borne on brown, septate,
knobby, sparingly branched conidiophores borne in clusters.
The fungi may overwinter on infected plants and debris and
survive from one season to the next on diseased leaves, stems,
and seeds. When infected seeds are planted, they may
produce weak, stunted seedlings with lesions on the
cotyledons; in a few days the growing fungus begins producing
conidia and secondary infections (Lucas et a1. 1985). The
conidia are wind blown or splashed by rain or carried by
insects and machinery to nearby plants. They germinate
within a few hours and quickly penetrate leaf tissue. The
disease spreads rapidly during warm weather, particularly
with intermittent rain. It is more severe in pure plantations.
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FIGURE 34. Setora postornata (Hampson) (after Xiang Zhang, in
Cai and Xiao 1983. I-adult insect; 2-egg; 3-larva; 4-pupa; 5-
cocoon).
Fungicides should be applied in the treatment of seeds
and regularly in the seedbed and plantation. In the
plantation, fallen leaves, branches, and logging debris should
be burned as soon as possible to remove the food source for
fungi. However, it is also important to use disease-free or
disease-resistant seeds to create a disease free forest.
Pests
In China, species of the family Limacodidae (Lepidoptera),
including Setora postornata (Hampson), Cnidocampa
!Zavescens (Walker), and Parasa spp. are common leaf pests of
Xi. Shu. Setoro postornata (Hampson) (Fiaure S4) is found in
almost all provinces in the subtropical region and attacks at
least 126 species of plants (Cai and Xiao 1983). The adult
moth is 17-20 mm long, brown, with a wing span of 30-40 mm.
The full grown larvae are 23-36 mm long, yellowish green
with two blue lines and black tubercles along the back. The
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body has yellow or purplish red hairs. Two generations occur
per year. The larvae often form cocoons in the debris or
surface soils (depth < 1 cm). The adult moths show strong
phototaxis. Control methods are: (1) Collect overwinter
cocoons from the debris and surface and deeply bury them in
soils (> 30 ern). (2) Trapping moths attracted to lights in the
evening. (3) Biological control by parasitic wasps (Chrysis
shanghaiensis, Bracon sp., and Trichogramma sp.). (4)
Chemicals applied to control young larvae.
Actias selene ningpoana Felder (Saturniidae, Figure 35)
is another major leaf pest of Xi Shu. It is largely distributed in
the subtropical region of China, Malaysia, India, Sri Lanka,
and Burma. It also attacks the species of Liquidambar,
Pterocarya, Ulmus, Populus, Salix, Sapium, Juglans, and
Malus. The adult moth has a body 35-40 mm long, with green
wings up to 120 mm in length. The body has dense white
hairs. The eggs are yellow, 2 mm in diameter. Larvae are
black at early stages and become yellow at later stages. The
full grown larvae are 73-80 mm long, with yellow hairs.
Normally two generations occur per year. Control methods
include: biological control by parasitic wasps, destruction of
pupae, and trapping moths in flight using lights.
Recently, we found the blackheaded race of the fall
webworm [Hyphantria cunea (Drury), Actiidae, Figure 36] to
be a serious insect defoliator on Xi Shu in the United States.
A larva can eat 10-15 leaves a day (Figure 37 and Figure 38).
This fall webworm is a native of North America and Mexico. It
feeds on almost all shade, fruit and ornamental trees except
conifers. In the United States, H. cunea attacks at least 88
species of trees; in Europe, 230 species of trees, shrubs,
ornamentals, and annual plants; in Japan, 317 species are
plant hosts; and in China its diet includes at least 50 species of
fruit and forest trees (Cai and Xiao 1983, Johnson and Lyon
1991). The adult fall webworms emerge from over-wintering
pupae in late spring. They are small white moths with wing
spans of 30 to 42 mm. The base of the front legs varies in
color from red to orange. The blackheaded race deposit their
eggs as single-layer masses in mid-March. When the larvae
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FIGURE 35. Actias selene ningpoana Felder (after Peiyi Zhang, in
Cai and Xiao 1983. I-adult insect; 2-1arva; 3-pupa; 4-cocoon).
hatch, they are yellowish green to pale yellow with two rows
of dark tubercles along the back. Their heads are black, and
the bodies covered with fine hairs. Groups of larvae cover
foliage with webbing and feed inside it through mid-summer.
Larvae pass through as many as 11 stages of development.
When fully grown, larvae are yellowish or greenish with a
broad, dark stripe along the back, and measure about 25 mm
in length. Larvae leave webs to pupate in soil debris
Generations per year of the fall webworm range from one (in
Canada) to four (in East Texas) (Johnson and Lyon 1991).
Protection 87
a-~--··~ n" 5
FIGURE 36. Hyphantria cunea (Dury) (after Peiyi Zhang, in Cai
and Xiao 1983. 1-adult insect; 2-egg; 3-larva; 4-pupa; 5-cocoon).
Control methods for fall webworm include: (1) Prune and
burn branches with webs; (2) Use parasites and predators to
control the pest (50 species of parasites and 36 species of
predators of the fall webworm are known, Johnson and Lyon
1991). (3) Chemical and microbiological control measures are
generally used successfully. The most widely used microbial
biological control method is to spray bacterium BTK (Bacilus
thuringiensis var. kurstaki) on leaves around webs when
larvae are small or when last stage larvae wander outside of
the web (Ellis and Bradley 1992). Parasitic wasps (TeZenomus
bifidus Riley, ApanteZes hyphantriae Riley, and Meterorus
hyphantriae Riley) and nuclear polyhedrosis viruses (NPV)
are also effective in controlling fall webworms.
In addition, Phassus sinifer sinensis Walker (Hepialidae)
is relatively common stem pest of Xi Shu in China. It largely
attacks deciduous hardwoods. Chemicals are used to control
this insect. Other pests such as aphids, scales, and whiteflies
also attack Xi Shu and should be controlled if infestation
reduces the quantity of leaves available for drug production.
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FIGURE 37. The fall webworm (bluckheaded race) is II leaf pest of
Xi Shu in the United Slates (pholo by P. R. Blackwell. Tucker Cenler).
FIGURE 38. Larva of the faU webworm can eat 10-15 leaves a day
(photo by S. Y. Li, Tucker Cenler).
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Animals
There are no data available showing that animals feed on
Xi Shu. Alternatively, it has been reported that the leaves of
Xi Shu poison animals. Goats eating the plant leaves develop
hemorrhagic diarrhea, dehydration, muscle tremors, coma,
and death (Cao et a1. 1992). Regardless of lack of
publications on this issue, reports of grazing of Xi Shu by
certain species of deer and hogs have been reported and care
should be taken to protect young plantations. Further study
in this area is needed.
Other Problems
Frost damage is an important factor influencing the
growth and distribution of Xi Shu. In the southeastern United
States, frost damage is largely restricted to buds and thus
limits the height growth of the tree (Figure 39). In addition,
herbicides should be avoided in Xi Shu plantation
management because some herbicides such as 2,4-D [(2,4-
dichlorophenoxy)acetic acid] kill the tree.
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FIGURE 39. Frost damage of terminal buds is an important factor
influencing the height growth and wood quality of Xi Shu (photo by
T. R. Moore. XyloMed Research Foundation).
13. HARVEST OF XI SHU
Planting at 17,780 seedlings per hectare (7,000 seedlings
per acre) yields about 6,750 kg (15,000 pounds) of air-dry
woody raw material per acre after three growing seasons
(Perdue 1968). Yields can be increased by wider spacing and
delayed harvest. Xi Shu has great ability to coppice. This
aggressive resprouting may indicate possible multiple
harvests during a single season. Plantations are suitable for
mechanical harvesting.
Harvesting can also be selective. For example, every
other row can be cut to thin the plantation and provide the,
remaining trees more room for growth.
Harvested seedlings should be cut slightly above ground
level and spread on the ground in direct sunlight to dry the
leaves. Since they have lower content of camptothecins than
other parts. leaves should be dried until they fall off the
branches so that they can be separated from the woody parts.
Roots are harvested with a hydraulically operated knife
attached to a tractor. The roots should be washed to make
certain that there are no other roots, clinging rocks or other
things that could damage the chipper blades. After chipping,
all woody material should be spread out on polyethylene
tarps to dry. Dry material can be sacked in bags for shipment
and chemical extraction.
Harvest season and age of tree are important factors
influencing drug quality. In particular, these two factors plus
location constitute three basic conditions of Daodi (mifu,
genuine, optimum) medicine in China and are always
emphasized in drug selection by Chinese doctors. Many
studies also show that the quantity of extractable chemical
compound varies with location, collection season, and age of
the tree. This provides scientific support for the Daodi
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tradition (Nie and Li 1989, Li et al. unpublished). According to
T. Kawahara and co-workers (1968), maximum dry weight of
the leaves (0.45 kg/m2 ) was reached in July, that of the
branches, stems, and roots and consequently of the nutrients,
in September. However, Perdue and co-workers (1968)
claimed that season of collection and age of tree have little or
no influence on the yield of CPT. If true, maximum CPT
production would be achieved by harvesting trees when they
produce maximum yields of dry matter. But the conclusions
of Perdue and co-workers (1970) are based on observation of
only 20 specimen trees. Thus, both sample size and
representiveness seem inadequate for a general picture of the
chemogeography of Xi Shu. At a minimum, the influence of
collection season, location, and tree age on drug quality
should be re-examined based on a large set of samples in
order to assure maximum drug recovery.
14. FURTHER RESEARCH
In brief, Xi Shu is a very valuable tree. Camptothecins,
the drugs extracted from this tree, have unique mechanisms of
action and thus exhibit potent anti-tumor and anti-viral
activities. The tree has advantages over Pacific yew in fast
growth and use of all plant parts for drugs. Thus, it is
expected that Xi Shu will be a favored source of drugs for the
treatment of cancers and even some virus diseases in the near
future.
Presently, large scale commercial synthesis of CPT and its
analogs is not feasible and living plants are the only practical
supply source. However, Xi Shu supply is a critical problem
in the United States. A three-year-old seedling produces
about 1 kg of dry woody material (Perdue 1968) or 50 mg of
CPT or its analogs. Each cancer patient is expected to need 1-
3 g of drug, which equates to 20-60 three-year-old seedlings of
Xi Shu. In 1993, about 1,170,000 people in the United States
were diagnosed as having cancer, and the number is
increasing. To treat only 30% of these patients, about 7-21
million young trees are needed annually. This requires 4,200-
12,600 hectares (about 10,500-31,500 acres) of plantations
(5,085 treeslhectare or 2,000 trees/acre, 3 year harvest cycle)
to meet the foreseeable demand in the United States alone. If
there are 22,200 good seeds per kg (about 10,000 good seeds
per pound) of dry fruits and 80% germinate, about 400-1,200
kg (881-2,643 pounds) of dry fruits are needed annually to
establish Xi Shu plantations. This requires about 200-600
mature trees to supply these seeds.
Additionally, AIDS is one of the most serious health
problems that the United States, or the world, has ever faced.
Some 17 million people around the world are infected by the
HIV. According to A. C, Novello, Surgeon General of the
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United States about one million Americans-1 in every 250--
are infected with HIV. In the next 10 years, more Americans
of all ages are expected to develop this disease. Between 1981
and 1992, more than 250,000 Americans developed AIDS and
more than 170,000 died. In 1994, it is estimated that 47,000 to
66,000 more Americans may die of AIDS and 40,000 to 80,000
will be newly infected with HIV. CPT and its analogs show
activity against many viruses including HIV-l. The drugs give
a new direction for HIV treatment. If camptothecins prove
useful in virus disease clinical trials, the annual need for Xi
Shu for treatment of HIV will exceed that for cancer.
Probably, up to 40 million young trees will be needed
annually for HIV treatment. This is the annual supply
needed to treat only 30% of the most seriously ill patients with
HIV in the United States. In addition, camptothecins are
potent drugs for many other serious diseases, such as psoriasis
and DNA viruses, and for plant growth regulation. In total, it
is expect that up to 100 million young trees could be needed
annually in the United States to meet this demand. This
requires up to about 60,000 hectares (about 150,000 acres) of
Xi Shu plantations in the United States (in terms of 5,085
treeslhectare or 2,000 trees/acre). However, at present less
than 10 acres of plantations exist in the United States.
The establishment of an optimum plant supply system
must solve the following problems based on chemical,
economic, and ecological principles: Where? In which region
and habitat does the tree grows fastest and also contain the
highest content of active compounds? What? Which part or
parts of the plant are the best for drug production? How and
When? How to harvest the plant and in what season. A
research model to establish such a production system is as
follows (Figure 40).
1. Evaluation and selection of ecotype. Xi Shu is widely
distributed in 12 provinces in China and grows naturally in
varied habitats from 200 m to 2,400 m in elevation. This
polygamo·monoecious species has great genetic variation
among geographic locations, among sites, among stands, and
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FIGURE 40. Research steps for establishing an optimum plant
supply system for Xi Shu.
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among trees. Current studies on genetic variation within this
species are not available. Also, the present seed source in the
United States is largely confined to a few parent trees. Such a
narrow range of available plant germplasm may limit
optimum forest production. Thus, it is advisable to evaluate
and select ecotypes or genotypes that display a high content of
the active chemical substances, are fast-growing and adapt to
cultivation. The primary selection can be conducted within
the native range of the tree in China. For long-term study, it
will probably be necessary to package all desired qualities
into improved individuals through hybridization.
2. Propagation. It is not difficult to propagate seedlings
from seeds. The seed supply and source is a problem for
commercial production in the United States at present and
even in the near future. An adequate supply is not available
within the United States, and it is doubted that China will
want to export seeds of such a valuable tree. On the other
hand, reproduction by seed in the absence of broad genetic
parental diversity causes filial regression. Vegetative
reproduction (by cuttings or micropropagation), however,
allows quick and large gains because genetic variation of the
selected ecotypes can be captured. According to our studies, it
is not difficult for shoot cuttings to produce roots. Tissue
culture studies were performed in Japan two decades ago
(Sakata and Misawa 1974) and very recently in the Morris
Arboretum at the University of Pennsylvania (Meyer 1991, P.
White pers. camm., May 1994), Stephen F. Austin State
University and Louisiana State University. But these studies
are still in the laboratory stage. Thus, reproduction by
cuttings (shoot, root, and bud) and micropropagation is needed
to produce the optimum forest for drug production.
3. Production Ecology. Production ecology of CPT and its
analogs of the selected ecotype should be the next step. It is
important in growing the tree to know how light,
temperature, water, soil nutrition, and biotic factors influence
the growth and chemical production of the tree.
Camptothecins are nitrogen-bearing compounds. Xi Shu
proved responsive to nitrogen fertilizer (Smith 1969).
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Therefore, introduction of some nitrogen fIxing plants into the
Xi Shu plantation can be expected to improve the growth of
trees. In addition, this tree is apparently eaten by many
insects, and pest control is an important part of production
ecology.
4. Harvest Methods and Seasons. Studies of drug
collection methods and seasons are needed. All parts of the
tree can be used for medicine. Fruits may have the highest
content of the needed chemical compounds among all parts of
the tree, but total production is not as high as in the bark.
Bark collection is a good option in drug production. Stripping
the bark of a tree will kill the tree. An approach to peel the
bark of living trees is needed both economically and
ecologically.
5. Establishment of the optimum plant supply system.
After the establishment of an initial tree supply system, it is
important to evaluate all factors in this system and
continuously modify the system.
In addition, new approaches for recovery of camptothecins
should be considered. First, two species of fungi Cercospora
camptothecae Tai and Pseudocercospora camptothecae Liu et
Guo are parasitic on Xi Shu (Liu and Guo 1987). Also,
Dendrobium nobile cultivated on Xi Shu contains unknown
alkaloids not found in wild D. nobile (Wang et a1. 1985). [f
these fungi concentrate CPT, as the parasitic fungus on the
Pacific yew continues to produce taxol even when it is
removed from the tree, it may be possible to grow large
quantities of fungi in vats and lower the cost of the drug.
Chemical studies are also needed for species (e.g., Nyssa
and Davidia) related to Xi Shu. Early data from the CCNSC
Screening Laboratories of Ncr are not promising. However,
two problems exist with these studies: (1) most tests used
twigs and leaves and usually these parts contain very low
concentrations of chemical compounds relative to fruits and
root bark; (2) only a limited number of samples were tested.
Thus, it may be possible to realize better results if based on a
larger number of samples of fruits and root bark of Nyssa.
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The conclusion is that the Xi Shu is a candidate for further
study in the effort to control some cancers and virus diseases.
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APPENDIX
Climatic Factors in the Natural Range of Xi Shu in
China and the Potential Range in the Southeastern
United States
Data Sources: 1. World-Climates (by B. W. Rudloff, Wissenschaftliche
Verlagsgesellschaft mbH Stuttgart, 1981); 2. The Times Books World
Weather Guide (by E. A. Pearce and G. Smith, Times Books Random
House, 1990)j 3. Physical Geography of China (by S. Q. Zhao, Science
Press and John Wiley & Sons, 1990); 4. Weather of U.S. Cities (fourth
edition, edited by F. E. Bair, Gale Research Inc., 1992).
Temperature: Fahrenheit from Celsius: OF = 1.8 x °C + 32
Precipitation: 1 in =25.4 mm
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Table 1. Mean percentage of possible sunshine in the natural range of Xi Shu in China and potential
range in the southeastern United States (1961-1990). (%)
Location Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Ann
CHINA
Shanghai 45 39 3R 30 38 40 57 6] 48 50 47 45 45
Wuhan. Hubei 40 36 33 38 42 51 61 67 55 49 45 43 47
Nanchang, Jiangxi 37 25 25 23 26 30 46 67 75 66 58 49 44
Chengdu. Sichuan 24 21 25 28 32 32 39 42 25 19 21 21 28
GuangLhou. Guangdong 42 27 21 25 38 40 56 55 S4 66 59 50 44
Guilin. Guangxi 24 13 16 27 28 36 44 54 56 41 38 41 34
Kunming. Yunnan 73 74 76 73 59 37 36 45 47 44 6S 68 58
Mean 41 34 33 35 38 38 48 S6 51 47 48 45 43
Table 1. (continued).
Location Jan Feb Mar Apr May Jun Iu] Aug Sep Oct Nov Dec Ann
UNITED STATES
Houston, Texas 43 48 SO 54 58 64 66 65 62 61 49 5] 56
Corpus Christi, Texas 45 SO 55 56 60 73 80 77 68 68 55 45 61
Little Rock, Arkansas 46 54 57 62 68 73 71 73 68 69 56 48 62
Shreveport. Louisiana 50 55 57 59 64 7] 74 73 69 69 58 52 63
Lake Charles, Louisiana 59 60 73 76 75 81 80 76 76 71 60 52 70
Tupelo, Mississippi 60 54 62 75 74 74 72 71 69 63 55 50 65
Jackson. Mississippi 49 53 60 65 63 71 65 66 62 66 56 49 60
Montgomery, Alabama 48 53 59 65 64 64 62 64 62 65 56 50 59
Savannah, Georgia S5 58 62 70 68 6S 63 62 57 64 62 55 62
Greenville, S. Carolina 57 60 64 67 62 63 61 61 62 66 60 55 62
Columbia, S. Carolina 56 59 64 69 68 67 66 66 64 66 63 59 64
Charleston, S. Carolina 57 60 65 7] 69 65 66 63 60 63 59 56 63
Jacksonville, Florida 59 62 67 72 70 64 63 62 57 59 60 56 63 >
Apalachicola, Florida 58 6] 65 74 78 71 64 64 66 74 67 57 67 "U"U
Mean 53 56 61 67 67 69 68 67 64 66 58 48 63 l'tl::lQ..
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Table 2. Monthly mean temperature in the natural range of Xi Shu in China and potential range in the ><southeastern United States (1961-1990). rC) ~
U"J
Location Jan Feb Mar Apr May Jun JuI Aug Sep Oct Nov Dec Ann IeCHlNA
Nanjing, Jiangsu 2 4 9 ]5 20 25 28 28 23 18 II 5 16
Shanghai 3 4 8 ]4 ]9 23 27 27 23 18 12 6 15
Yichang, Hubei 6 7 ] ] ]8 22 26 29 29 24 19 13 8 ]8
Wuhan, Hubei 4 6 10 17 21 27 30 30 25 19 13 7 17
Jiujiang, Jiangxi 5 6 10 17 22 26 30 29 24 19 13 7 17
Nanchang, Jiangxi 6 7 10 16 21 25 29 30 25 19 14 7 17
Changsha, Hunan 4 6 11 17 23 26 30 30 26 19 16 7 ]8
Chengdu, Sichuan 6 8 13 18 22 24 26 26 22 18 12 8 17
Chongqing, Sichuan 7 10 ]5 19 23 25 29 30 25 19 14 11 19
Aiamcn, Fujian ]4 13 16 17 24 27 29 29 28 25 21 17 22
Guangzhou, Guangdong 14 ]4 17 22 26 27 28 28 27 24 20 16 22
Guilin, Guangxi 9 10 13 19 24 24 28 28 26 22 16 11 ]9
Longzhou, Guangx.i 14 15 19 23 27 29 29 29 28 24 ]9 18 23
Kunming, Yunnan 10 11 14 18 20 20 20 20 18 16 12 10 ]6
Tengchong, Yunnan 8 10 ]3 16 18 20 20 21 20 17 16 9 16
Mengzi, Yunnan 14 ]6 19 22 24 24 24 24 23 20 ]6 14 20
Mean 8 9 13 18 22 25 27 27 24 20 15 10 18
Table 2. (continued).
Location Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Ann
UNlTED STATES
Houston. Texas 11 13 16 20 24 27 28 28 26 21 16 12 20
Corpus Christi, Texas 14 IS 19 23 26 28 29 29 28 23 18 15 22
Little Rock. Arkansas 4 7 II 17 21 26 28 27 24 17 ]] 6 17
Shreveport. Loui siana 8 10 14 19 23 27 28 28 25 19 13 9 19
Lake Charles. Louisiana 1I 12 16 20 24 27 28 28 26 21 15 12 20
Baton Rouge, Louisiana 10 12 16 20 24 27 28 27 26 20 15 12 20
Tupelo. Mississippi 5 7 11 17 21 25 27 27 23 17 1J 7 17
Jackson, Mississippi 8 10 14 18 23 26 28 27 25 18 12 9 18
Montgomery, Alabama 8 10 14 18 22 26 28 27 25 19 13 9 18
Mobile, Alabama 10 12 16 20 24 27 28 28 26 20 15 12 20
Huntsville, Alabama 5 6 11 16 20 25 26 26 23 16 10 6 16
Savannah. Georgia 10 11 15 19 23 26 27 27 25 19 ]4 11 19
Athens, Georgia 6 7 11 17 21 24 26 26 23 I7 Jl 7 16
Greenville. S. Carolina 5 6 16 16 20 24 26 25 22 16 11 6 16 1>--Columbia, S. Carolina 7 8 13 18 22 25 27 27 24 17 12 8 17
Charleston. S. Carolina 9 10 14 18 22 25 27 27 24 19 14 10 18 I~Jacksonville, Florida 12 13 16 20 23 26 27 27 26 21 16 13 20Gainesville, Florida 13 13 17 20 24 26 27 27 26 21 17 13 20Apalachicola. Florida 12 13 16 20 24 27 28 27 26 21 16 13 20
Mrean 9 10 14 19 23 26 28 27 25 19 14 10 19
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Table 3. Monthly mean precipitation in the natural range of Xi Shu in China and potential range in the I~southeastern United Stales (1961·1990). (mm) ~
Location Jan Feb Mar Apr May Jun lui Aug Sep Oct Nov Dec Ann Ie
CHINA
Nanjing, Jiangsu 41 51 76 102 81 183 206 117 94 51 41 30 1073
Shanghai 49 62 85 91 96 177 148 139 132 74 53 38 1144
Yichang, Hubei 23 30 48 99 124 158 208 178 102 74 33 18 1095
Wuhan, Hubei 46 48 96 152 165 244 180 96 71 81 48 28 1255
liujiang, Jiangxi 64 84 150 180 175 244 142 132 89 96 69 43 1468
Nanchang, Jiangxi 55 108 192 250 289 295 258 111 109 57 70 70 1864
Changsha. Hunan 48 94 135 145 208 221 112 109 69 76 69 38 1324
Chengdu, Sichuan 7 15 25 56 96 122 304 303 139 53 18 8 1146
Chongqing, Sichuan IS 20 38 99 142 180 142 122 150 t 12 48 20 1088
Aiamen, Fujian 33 76 89 124 158 178 132 168 109 48 30 33 1178
Guangzhou, Guangdong 27 6S 101 185 256 292 264 249 149 49 51 34 1722
Guilin, Guangx.i 51 79 161 223 259 370 236 200 101 87 53 47 1867
Longzhou, Guangx.i 20 36 48 81 178 216 229 231 142 64 30 20 1295
Kunming, Yunnan 3 18 21 31 99 192 214 220 161 95 31 11 1096
Tengchong, Yunnan 13 38 36 69 128 236 312 282 163 15R 41 23 1499
Mcngzi. Yunnan & 18 28 41 127 132 196 198 96 51 56 15 966
Mean 31 53 83 121 161 215 205 178 117 77 46 30 1317
Table 3. (continued).
Location Jan Feb Mar Apr May lun Jul Aug Sep Oct Nov Dec Ann
UNITED STATES
Houston, Texas 82 83 68 108 119 103 85 93 125 93 86 93 1137
Corpus Christi, Texas 41 39 21 51 77 85 50 89 156 81 39 36 767
Little Rock, Arkansas 99 97 119 137 134 93 92 78 108 72 111 107 1250
Shreveport, Louisiana 102 88 96 120 119 90 90 64 84 67 96 98 1114
Lake Charles, Louisiana 108 99 77 103 131 106 141 137 132 88 96 129 1347
Baton Rouge, Louisiana 116 126 117 142 !22 79 180 128 112 67 1()() 127 1417
Tupelo, Mississippi 144 1I8 176 144 133 94 117 72 92 76 118 142 1425
Jackson, Mississippi 127 114 149 149 123 75 112 94 90 67 106 137 1342
Montgomery, Alabama 107 116 150 111 102 88 121 81 120 58 76 121 1249
Mobile, Alabama 117 125 165 136 139 129 197 171 167 67 93 138 1642
Huntsville, Alabama 131 122 172 125 117 95 129 79 101 74 108 138 1390
Savannah, Georgia 78 81 97 80 117 145 187 169 131 58 48 70 1262
Athens, Georgia 123 106 148 103 121 IOI 132 92 91 69 84 104 1274
Greenville, S. Carolina 107 112 149 110 107 121 104 93 lID 89 82 100 1283
Columbia, S. Carolina III 101 131 91 98 113 136 141 107 65 64 89 1248 >Charleston, S. Carolina 85 86 III 66 112 166 186 165 125 74 55 79 1310 'ti
Jacksonville, Florida 78 88 94 84 125 136 166 182 184 87 49 66 1340 ""0~
Gainesville, Florida 82 100 90 75 105 161 178 205 140 62 52 82 1330 ='
Apalachicola, Florida 89 92 103 83 75 122 180 191 220 81 72 89 1396
p..
....
><
Mean 101 I()() 118 106 115 111 136 122 126 73 81 102 1291
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Table 4. Monthly mean relative humidity in the natural range of Xi Shu in China and potential range in
the southeastern United States (1961-1990). (%)
Location Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Ann
CHINA
Shanghai 74 78 78 80 82 84 83 82 81 77 78 77 80
Wuhan, Hubei 76 78 81 81 80 78 79 78 77 77 79 77 79
Chcngdu, Sichuan 79 81 78 78 77 81 85 85 85 86 83 83 82
Chongqing, Sichuan 87 88 87 86 87 86 80 76 84 88 91 91 86
Guangzhou, Guangdong 69 78 83 84 85 86 84 83 80 72 69 68 78
Kunming, Yunnan 68 62 58 56 64 78 83 84 82 82 76 73 72
Mengzi, Yunnan 55 53 48 50 57 64 69 70 66 67 67 56 60
Mean 73 74 73 74 76 80 80 80 79 78 78 75 77
Table 4. (continued).
Location Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Ann
UNITED STATES
Houston, Texas 74 73 72 73 75 75 75 75 77 76 77 75 75
Corpus Christi, Texas 78 76 74 77 80 78 75 75 77 76 77 76 77
Little Rock, Arkansas 70 68 66 67 72 70 72 72 74 71 71 71 70
Shreveport, Louisiana 72 69 67 70 73 73 72 71 73 72 73 74 71
Lake Charles, Louisiana 79 77 77 76 78 78 80 80 80 77 78 80 78
Baton Rouge, Louisiana 74 71 70 71 73 75 77 78 77 74 75 75 74
Tupelo, Mississippi 70 70 65 63 71 70 73 73 73 73 72 72 70
Jackson, Mississippi 76 73 71 72 74 74 77 77 78 77 78 78 76
Montgomery, Alabama 70 67 66 68 71 72 76 77 74 73 73 72 71
Mobile. Alabama n 70 71 71 72 74 77 78 76 n 74 74 74
Huntsville, Alabama 73 69 67 65 71 72 75 75 76 73 72 72 72
Savannah, Georgia 69 66 67 66 71 74 76 79 79 74 73 71 72
Athens, Georgia 69 66 65 64 70 72 76 77 77 74 71 70 71
Greenville. S. Carolina 66 64 63 62 69 71 74 76 77 72 70 69 70
Columbia, S. Carolina 70 66 66 63 69 71 74 78 78 76 74 72 71 >Charleston, S. Carolina 72 70 70 70 74 77 79 81 81 77 75 73 75 ""Cl
Jacksonville. Florida 76 73 71 71 72 76 77 80 81 79 78 78 76 '"0rt>
Gainesville, Florida 78 75 76 72 73 79 82 84 84 81 83 82 79 ::sp..
Apalachicola, Florida 78 78 78 77 77 78 80 82 80 77 78 79 79
_.
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Mean 73 71 70 69 73 74 76 77 77 75 75 74 74
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Table 5. Extreme temperatures in the natural range of Xi Shu in China and potential range in the
southeastern United States (1961-1990).
Location Latitude Longitude Highest Temp. Lowest Temp. Difference
CC) CC) CC)
CHINA
Nanjing, Jiangsu 32"MN 118"47'E 43.0 -13.8 56.8
Shanghai 3l"l2'N 12J"26'E 40.2 -12.1 52.3
Wuhan, Hubei 3O"33'N 114"17'E 41.3 -13.0 54.3
Nanchang, Jiangxi 28"4O'N I IS"S8'E 39.4 -5.9 45.3
Changsha, Hunan 28'15'N II2"5O'E 43.0 --&.1 51.1
Chcngdu, Sichuan 3Oo4ON IMo04'E 40.1 --4.0 44.1
Chongqing. Sichuan 29°3O'N 1<X>"33'E 44.0 -25 46.5
Wenzhou, Zhejiang 28"01N 120"49E 40.5 -3.0 43.5
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Table 5. (continued),
Location Latitude Longitude Highest Temp. Lowest Temp. Difference
("C) ( °C ) ( "C)
UNITED STATES
Houston, Texas 29°S8'N 95°21'W 41.7 -13.9 55.6
Corpus Christi, Texas 2T46'N 9T30'W 40.0 -10.6 50.6
Little Rock, Arkansas 34°44'N 92'14'W 44.4 -20.5 64.9
Shreveport, Louisiana 32°28'N 93°49'W 41.7 -16.1 57.8
Lake Charles, Louisiana 30·0TN 93'13'W 38.9 -11.7 50.6
Baton Rouge, Louisiana 30'32'N 91'08'W 39.4 -13.3 52.7
Tupelo, Mississippi 34"16'N 88'46'W 40.6 -21.1 61.7
Jackson. Mississippi 32' 19'N 90'05'W 41.1 -16.6 57.7
Montgomery, Alabama 32°18'N 86'24'W 40.6 -17.8 58.4
Mobile, Alabama 30'41'N 88°15'W 40.0 -16.1 56.1
Huntsville. Alabama 34'39'N 86'46'W 39.4 -23.9 63.3
Savannah, Georgia 32°08'N 81'12'W 40.6 -16.1 56.7
Athens, Georgia 33'5TN 83'19'W 41.7 -20.0 61.7
Greenville. S. Carolina 34"54'N 82"3'W 39.4 -21.1 60.5 >
Columbia, S. Carolina 33'STN 81 0 0TW 41.7 -18.3 60.0 'lj
'lj
Charleston, S. Carolina 32°54'N 80'02'W 40.0 -14.4 54.4 ro
Jacksonville, Florida 30'30'N 81'42'W 40.6 -13.9 54.5 ~0..
Gainesville, Florida 29'41'N 82°16'W 38.9 -12.2 51.1
_.
><
Apalachicola. Florida 29"44'N 85'02'W 38.9 -12.8 51.7
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